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Abstract
Glioblastoma (GBM) is the most common and lethal primary brain cancer in adults despite
aggressive treatments with surgery and chemo-radiation. Advances in electrotherapeutics
offer a foundation for developing new treatment modalities that exploit an innate
vulnerability of glioblastoma (GBM). Low intensity, non-ablative electric fields are
innocuous to normal neural structure, but incite GBM cell apoptosis by putatively disrupting
cytokinesis and transmembrane ion homeostasis. Our collaborative research group is
pioneering a new electrotherapeutic technology for GBM called Intratumoral Modulation
Therapy (IMT) which uses customized, implanted bioelectrodes to deliver sustained,
titratable and focused therapeutic electric fields into tumor-affected brain regions. My work
has confirmed and expanded the group’s previous in vitro evidence of IMT efficacy against
GBM and diffuse intrinsic pontine glioma (DIPG) and has demonstrated potent antineoplastic, pro-apoptotic effects of IMT in vitro without significant impact on non-cancerous
post-mitotic neurons. The co-application of IMT also potentiates the benefits of
chemotherapy and gene therapy. We have created a robust in vivo IMT model using allograft
GBM cells in Fischer rats to test the efficacy of IMT in vivo. The GBM animal studies to
date have demonstrated proof-of-concept efficacy of IMT against GBM using rudimentary,
single-contact bioelectrodes. However, single-contact electrodes cannot adequately
accommodate the entire tumor or GBM resection bed where recurrence is otherwise
inevitable. To translate this technology to clinical use, new special purpose bioelectrodes
must be designed and tested to optimize and contour IMT coverage. This thesis yielded key
insight into the bioelectrode configuration and treatment settings for effective and safe IMT
delivery in GBM and DIPG. Advances in this technology will facilitate clinical translation of
IMT as a critically needed therapy for these devastating brain cancers.
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Summary for Lay Audience
High-Grade Gliomas (HGG) are deadly brain tumors with very poor treatment outcomes.
Glioblastoma (GBM) and diffuse intrinsic pontine glioma (DIPG) are categorized as highgrade gliomas (HGGs) and remain among the most deadly brain cancers in adults and
children, respectively. Treatment only extends life approximately 12 months, therefore
research into new therapies is crucial. Our team has developed a new biotechnology called
Intratumoral Modulation Therapy (IMT). This technology uses an implanted electrical
system to treat and kill tumors within the brain. IMT has shown to be an effective first line
treatment and enhances the effects of chemoradiotherapy. We hypothesized that IMT
delivered via specially designed, implantable bioelectrodes within HGG tissue or resection
cavity (where these tumors always recur in a short time after surgery) will slow HGG growth,
kill tumor cells, and increase the sensitivity of HGG to standard chemotherapy and radiation.
Advanced brain imaging techniques were used to assess tumor growth and survival alone and
in combination with standard doses of chemotherapy and radiation. The clinical vision of
IMT is to provide a concealed, anatomically focused, patient-specific therapy that can
effectively fight these cancers and enhance the benefits of existing treatment options. The
results of this project have provided key information used to advance IMT towards clinical
application. The successful development of IMT technology has the potential to markedly
improve the survival and quality of life for patients facing these deadly cancers.
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Chapter 1

1

General Introduction

1.1 Glial Tumors
Glial tumors are primary malignant tumors of the central nervous system (CNS). The
World Health Organization (WHO) categorizes these tumors as diffuse astrocytic tumors,
other astrocytic tumors, oligodendroglia tumors, and other gliomas. Glial tumors arise
from the glial cells within the brain such as astrocytes, oligodendrocytes, and ependyma
cells [Louis, 2016; Rushing, 2021]. An emerging hypothesis suggest that progression of
glial tumors is driven by a small subpopulation of tumor stem cells, termed cancer stem
cells [Das, 2008]. These cells likely arise from mutations in neural progenitor cells and
demonstrate the capability to self-renew, proliferate, and give rise to multiple
neuroepithelial lineages [Cahill, 2018]. In Europe and North America, glial tumors have
an incidence of approximately 21.5/10,000 people per year [Louis, 2016; Ostrom QT
2016], with men having a higher risk of developing glioma than women [McKinley,
2000]. The WHO describes a systematic method for grading CNS tumors from Grade IIV to predict the biological behavior, choice of therapy, and prognosis [Louis, 2016;
Rushing, 2021]. Low-grade gliomas encompass grades I and II which generally have low
proliferative potential and are associated with favorable patient outcomes. Grade I
gliomas may be cured with surgical resection and are associated with long-term survival
[Louis, 2016]. Grade II gliomas are also usually relatively slow growing; however, some
can infiltrate into the surrounding brain parenchyma and transform into high grade
tumors. High-grade gliomas (HGG) include grade III anaplastic astrocytoma and grade
IV glioblastoma (GBM). HGGs display histological evidence of diffuse malignancy,
nuclear atypia, brisk mitotic activity, and necrosis. Molecular diagnostics in CNS tumor
classification has identified tumor families grouped according to genetic mutations, such
as in genes for isocitrate dehydrogenase (IDH) and Histone H3. These molecular
signatures have provided predictive prognostics, molecular biomarkers, and led to the
refinement of glioma classification [Masui, 2016; Fan, 2021]. GBM accounts for 60-70%
of HGGs in adults, the other 30-40% is made up of anaplastic astrocytoma (15%) and
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oligodenroglial tumors (e.g., oligodendrogliomas, oligoastrocytoma;10%). Another ~10%
includes anaplastic variants of ependymoma and ganglioglioma [Rushing, 2021]. The
median age of onset of HGGs in adults is 45 years and 60 years for Grade III and Grade
IV tumors, respectively. Approximately 90% of HGG cases are de novo in nature
[Ostrom, 2014] with the remaining 10% of tumors corresponding to a previous history of
lower grade glioma transforming into HGG [Louis, 2016]. In pediatric neuro-oncology,
HGG are the most common CNS neoplasms in children between the ages 10-15 years old
[Bondy, 2008], and represent approximately 8–12% of all pediatric CNS tumors
[Fangusaro, 2012]. Brainstem gliomas such as diffuse intrinsic pontine glioma (DIPG)
affect approximately 300 children in the United States per year and are the leading cause
of death in children with brain tumors [Williams, 2020; Kaatsch 2001].

1.1.1

Glioblastoma

Glioblastoma (GBM) represents the most common primary brain tumor in adults,
accounting for approximately 15% of intracranial neoplasms and 45-50% of all primary
malignant brain tumors. In Europe and North America, the incidence of GBM is
approximately 4/100,000 of the population [Holland, 2000]. GBM is characterized by a
diffuse and infiltrative growth pattern and will often cross the corpus callosum into the
contralateral hemisphere, rendering the tumor inoperable. GBM rarely invades into the
subarachnoid space and metastases beyond the CNS are seldom reported [Wen, 2008].
Histologically, GBM displays brisk mitotic activity, increased cellularity, nuclear atypia,
and a wide range of intra and intertumoral heterogeneity [Berens, 1999] The presence of
tissue necrosis is also commonly found in GBM.
GBM can occur de novo (95%) or, less commonly, progress from a lower grade glioma
[Ohgaki, 2004]. It may be further subdivided into (1) isocitrate dehydrogenase (IDH)
wildtype (about 90% of cases), which is more often associated with primary or de novo
GBM [Louis, 2016]; (2) IDH1 R132H mutant (about 10% of cases) is more often
associated with a previous history of lower grade diffuse glioma with transformation to
GBM in younger patients [Rushing, 2021]. IDH-wildtype GBM may be characterized by
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gene amplification of epidermal growth factor receptor (EGFR), loss of heterozygosity
(LOH) of chromosome 10q containing phosphatase and tensin homolog (PTEN) genes,
and deletion of p16 [Yan, 2009; Davis, 2016]. IDH-mutant GBM tumors may harbor
mutations in TP53 and retinoblastoma (Rb) genes, overexpression of genes for plateletderived growth factor A and platelet-derived growth factor receptor alpha
(PDGFα/PDGFRα), and LOH of 19q, however there may be overlap in the genetic
signatures with IDH-wildtype [Yan, 2009; Davis, 2016]. The molecular characterization
of GBM is a complex emerging science, and the role of genes in classifying GBM
subtypes remains poorly understood. Studies have reported that the IDH1 mutation is
associated with both increased overall and progression-free survival in patients with
GBM [Yan, 2009].
The presentation of newly diagnosed GBM can vary widely depending on the size,
location, and the anatomical structures affected within the brain [Alexander, 2017;
Young, 2015]. Patients with GBM often present with subacute neurological symptoms
and may have signs of increased intracranial pressure, including headache and focal or
progressive neurologic deficits [Hanif, 2017]. Initial diagnosis is made utilizing medical
imaging, including computed tomography (CT) and magnetic resonance imaging (MRI).
Treatment of GBM requires a multidisciplinary approach. The current standard of care
involves maximal safe surgical resection with adjuvant radiotherapy and temozolomide
(TMZ) chemotherapy. The main factors influencing the feasibility and extent of GBM
resection include involvement of eloquent CNS regions, patient age and comorbidities.
Extensive surgical resection of GBM may be limited when these tumors present in
eloquent brain regions, such as in areas implicated in motor function, sensation, vision,
and speech production. Even when radical surgical resection is possible, it is not curative
due to tumor cell invasion into the surrounding brain structures. The GBM cells that are
not captured by resection inevitably initiate tumor recurrence; therefore, local tumor
control with surgery remains poor (Wilson, 2014). Though surgical resection is not
curative, multiple studies have demonstrated that aggressive surgical resection when
possible is associated with a significant increase in both progression-free survival (PFS)
and overall survival [Kuhnt, 2011; Roder, 2014; Keles, 1999; Lacroix 2001; Mukherjee,
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2011; Stummer, 2006]. Surgery is also an option for some patients following disease
recurrence. Additional surgery can help alleviate mass effect and symptoms of recurrent
GBM; however, is generally a palliative procedure and may not enhance OS [Lukas,
2019; Bloch, 2012; McGirt, 2009; Brandes, 2013; Franceschi, 2015].
For many patients, major surgical resection is not feasible, and these patients may be
offered partial resection or stereotactic biopsy, which may be followed by chemotherapy
and radiotherapy. Depending on the degree of resection, the procedure can reduce
intracranial pressure and provide symptom palliation. The degree to which partial
resection increases overall survival is still debated and likely case dependent [Young,
2015]. Stereotactic biopsy may be offered when tumors are not safe to resect (e.g.,
infiltrating eloquent brain regions), or in patients with high-risk medical comorbidities or
who choose not to undergo a major resective operation. Stereotactic biopsy is indicated
to confirm diagnosis but is not an effective tumor treatment in and of itself. Optimal
standard of care including major resection and chemoradiation offers a median survival
of 14-16 months, whereas untreated GBM typically claims the lives of patient within
several weeks to months of diagnosis [Hanif, 2017]. Following maximal safe surgical
resection or biopsy, the patient commonly receives adjuvant radiation therapy (RT) with
a dose of 60 Gy in 30 fractions. RT beyond 60 Gy showed no additional survival benefits
and was associated with increased toxicity [Barani, 2015].
Concurrent TMZ is now a first line chemotherapy for GBM in many regions and
developed in part from a pivotal phase III clinical trial demonstrated that RT with
concomitant TMZ chemotherapy was more effective than RT alone [Stupp, 2005]. The
clinical trial showed that patients who received RT with concurrent TMZ had a median
survival of 14.6 months compared to 12.1 months seen with RT alone. TMZ is typically
given at a dose of 75 mg/m2 every day during radiation therapy, followed by a 6-week
rest period. TMZ maintenance dosing may then be continued for six 1-week cycles dosed
at 150-200 mg/m2 daily for five days, followed by two days of rest [Barani, 2015].
Despite maximal multimodality therapy, approximately 70% of patients will experience
disease recurrence and progression within one year of diagnosis [Stupp, 2005]. The
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prognosis for GBM patients remains dismal, with median survival of only 14 months
[Louis, 2007] and a 5-year survival of less than 5% [Ostrom, 2014; Batash, 2017].

1.1.2

Diffuse Intrinsic Pontine Glioma

Diffuse intrinsic pontine glioma (DIPG) represents ~15% of all pediatric brain tumors
and ~80% of pediatric brainstem gliomas, with an incidence of 0.14 per 100,000 [Lu,
2019]. These patients generally present between the ages of 5 and 11 years old with long
tract signs, ataxia, and cerebrospinal fluid obstruction developing over a period of several
months. In most centres, radiographic diagnosis without biopsy is made when a de novo
tumor is delineated in the midline of the neuraxis, most commonly in the pons [Williams,
2020]. The histopathology of pediatric HGGs overlaps with those of their adult
counterparts; however, DIPGs have distinct genetic alterations. Most tumor cells within a
DIPG harbour NCAM1, S100, and Olig2 mutations. Other mutations such as in GFAP,
MAP2, NeuN, and p53 are variable [Wu, 2012; Johung, 2017]. Subgroups of DIPG
express mutations in histone H3.3 (gene name H3F3A), K27M, or G34V/R. These
mutations have also been shown to be molecular drivers of pediatric GBM corresponding
to WHO grade IV and suggest a worse prognosis [Johung, 2017; Karremann 2018].
Due to diffuse infiltration of DIPG within eloquent brain regions, surgical resection is
often not safely feasible. The mainstay treatment includes steroid therapy at the time of
diagnosis, which aims to improve neurological symptoms by reducing tumor-associated
edema. Patients then undergo fractionated radiation therapy (RT) typically to achieve a
total dose of 54 Gy in 30 fractions [Gallitto, 2019]. RT is a palliative treatment that
improves neurological symptoms in ~80% of patients and prolongs survival by 2-3
months. Unfortunately, no chemotherapy drugs to date are known to have an impact on
survival. These limited therapies offer patients a median survival of 9 months and fewer
than 10% of children survive beyond 2 years [Karremann, 2018; Vanan, 2015; Fonseca,
2021].
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1.2 Electrotherapies for HGG
The rationale to develop electrotherapeutic strategies for GBM is based on a critical need
for new treatment approaches and the demonstrated vulnerability of rapidly proliferating
neoplastic cells due to disruptions in the electrochemical environment [Pless, 2011;
Davies, 2013]. Various types of tumor cells exposed to appropriate electrical stimuli may
also be sensitized to chemotherapy and radiation paradigms [Cadossi, 2014; Kim, 2016].
The therapeutic action of electrotherapy in cancer is likely mediated through various
cellular mechanisms that are contingent upon the frequency and amplitude of the applied
electric fields. For example, electrical stimulation applied to cells in culture may interfere
with the naturally occurring weak electric field present within cells. The cells use these
fields to arrange charged molecules, such as microtubules that form the spindle apparatus
during cytokinesis. The disruption of this process can impede spindle formation and
proliferation of tumor cells [Kirson et al., 2004]. Other potential mechanisms of the anticancer effect include disruption of ion homeostasis, lipid bilayer integrity, and gene
regulation. It is likely that each of these hypothesized mechanisms trigger unique
signaling cascades resulting in cell death through apoptosis or necrosis [Cemazar, 2012;
Weaver, 2012]. In the brain, highly proliferative HGG possess a greater susceptibility to
electrochemical perturbations compared to slowly dividing or post-mitotic neural cells
[Xu, 2016; Krison, 2004; Krison, 2014; Stuup, 2017]. The relative selectivity likely
reflects the brisk mitotic rate and metabolic instability of neoplastic cells and presents a
promising niche for electrotherapeutic development.

1.2.1

Putative Applications of Electrotherapy in Cancer

1.2.1.1 Electrochemotherapy
It is well established that administration of electric pulses can reversibly permeabilize
cells to allow molecules that are normally membrane impermeant, such as hydrophilic or
large molecules, to enter the cytosol [Neumann, 1988; Belehradek, 1993; Orlowski,
1988]. The earliest studies demonstrating that electrical stimulation could potentiate the
effects of chemotherapeutics were done in vivo in rats implanted with hepatocellular
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carcinoma. The combination of high-voltage electrical impulses (5 kV/cm, 2 msec)
administered following bleomycin (a poorly membrane-permeant cytotoxic agent)
significantly decreased tumor cell viability [Glass, 1996]. In 1988, Orlowski et al.
demonstrated that in vitro electropermeabilization of DC-3F sarcoma cells enhanced the
uptake and cytotoxicity of bleomycin. Combining bleomycin with reversible
electroporation increases the cytotoxicity of bleomycin by up to 10,000-fold [Okino,
1987].
Numerous clinical studies have been conducted using electrochemotherapy as a potential
treatment for different types of cancer. An early Phase 1/2 clinical trial demonstrated that
four or eight 100-microsecond pulses of 1300 V/cm administered via external electrodes
in combination with 10 mg/m2 bleomycin was safe and well-tolerated, with anti-tumor
effects demonstrated in nodules of head and neck squamous cell carcinomas [Mir, 1991].
Bleomycin-mediated electrochemotherapy has been shown to be clinically effective in
the treatment of basal cell carcinoma [Quaglino, 2008] subcutaneous metastatic breast
adenocarcinomas [Campana, 2008], metastases of malignant melanoma [Glass, 1996;
Quaglino, 2008; Campana, 2014], soft tissue sarcomas, [Belehradek, 1993] and
pancreatic adenocarcinoma [Granataa, 2015]. Thus, electrochemotherapy is effective in
the treatment of cutaneous, subcutaneous, and visceral tumors. Electrochemotherapy is
continuing to be developed to treat deeper tumors, such as those of the bone and internal
organs, using a pulse generator and long needle electrodes [Edhemovic, 2011].
Electrochemotherapy can be individualized based on the shape and the size of the tumor
[Pavlihaa, 2012], and mathematical models can assist in calculating specific electrical
pulse parameters to induce maximal necrosis inside the tumor mass, without affecting the
normal peripheral tissue [Edhemovic, 2011; Pavlihaa, 2012]. Mathematical modeling can
also predict the degree of blood brain barrier (BBB) disruption for adequate transfer of
chemotherapeutic

agents

to

the

tumor

mass

[Hjouj,

2012],

suggesting

electrochemotherapy may be a promising treatment for difficult to reach tumors in the
brain, such as GBM.
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1.2.1.2 Irreversible electroporation
Electroporation utilizes high voltage electrical pulses (hundreds to thousands of V/cm), to
enhance membrane permeability via the creation of nanoscale pores. [Weaver, 2000;
Ivorra, 2010]. Reversible electroporation has been used for years to enhance uptake of
chemotherapeutic drugs; however, higher intensity electroporation can in fact produce
irreversible pore formation as a monotherapy to destroy cells [Weaver, 1995]. This
technique is termed irreversible electroporation (IRE). IRE can destroy unwanted tissues,
similar to selective ablation therapies, such as radiofrequency, cryosurgery, or focused
ultrasound [Rubinsky, 2007]. IRE leads to cell death via creation of nanoscale aqueous
pores, resulting in membrane lysis, loss of homeostasis, loss of organelles, or influx of
cytotoxic molecules [Weaver, 1995; Cemazar, 2012]. IRE can selectively ablate
cancerous cells both in vitro and in vivo and has been tested clinically in tumors of the
liver, pancreas, kidney, lung, lesser pelvis, and lymph nodes [Scheffer, 2014].

1.2.1.3 Electrogene Therapy
The clinical use of gene therapies in cancer has been limited primarily due to the lack of
efficient and effective delivery methods for the genetic material. Similar to use of
electrical stimulation to enhance uptake of chemotherapeutics, electroporation or electropermeabilization techniques have been successfully utilized to deliver genetic material to
solid tumors by transiently permeabilizing the plasma membrane [Heller, 1996; Nishi,
1996]. These transiently formed pores act as non-specific aqueous channels and allow for
the passive diffusion of molecules less than 4 kDa across the plasma membrane,
including chemotherapeutics and siRNA [Bureaua, 2000]. Larger (greater than 4 kDa) or
charged molecules, such as plasmid DNA (pDNA), can also enter the cell when the Um
reaches 0.2-1 V through alternate mechanisms. pDNA is then actively transported to the
nucleus by cytoskeletal transport and can be expressed or incorporated into the host
genome [Vaughan, 2006]. There are notable challenges to the utilization of gene
electrotherapy in treatment of GBM. A principle of gene electrotherapy is the injection
and incorporation of DNA at the expected site of gene transfer. As GBM is a diffuse
neoplasm, this may limit the efficacy to an area of local administration. Furthermore,
much work needs to be done regarding the optimal electroporation parameters needed to
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permeabilize glial cells and facilitate gene transfer prior to developing brain-specific
protocols for human patients with GBM.

1.2.1.4 Alternating Electric Fields
In living cells, natural electric fields contribute to a host of physiological processes. For
example, polar molecules, such as microtubules, will orient along the line of a uniform
electric field, and when the field is not uniform, molecules move towards higher field
intensity in a process known as dielectrophoresis [Clague, 2005; Gonzalez; 2005]. The
application of low-voltage, alternating electric fields (AEFs) induces ionic flow
oscillations and dipole rotations that disrupt the organization and function of these
molecules [Giladi, 2015].
In vitro, AEFs have a strong inhibitory effect on growth and proliferation of many
cancers cell lines, including human GBM cells [Kirson, 2004; Kirson, 2007]. GBM cells
exposed to AEFs in culture can also potentiate the effects of chemotherapeutics [Kirson,
2009] and ionizing radiation [Kim et al., 2016]. Preclinical in vivo studies have also
demonstrated that AEFs can significantly inhibit tumor growth in a Fischer rat F98
glioma model [Kirson et al., 2007]. The prevailing theory for the mechanism of AEFs is
that in cells, polar molecules orient themselves along the lines of a uniform electric field.
When this field is not uniform, polar molecules move towards the higher field intensity. It
is hypothesized that low-intensity (1-3 V/cm), intermediate-frequency (100-300 KHz)
AEFs applied to cancer cells act on polarized microtubules and disrupt spindle formation
during metaphase. The resulting dielectrophoretic movement of polar molecules
organized along the weak electromagnetic field of the cell during cytokinesis leads to
mitotic arrest, membrane blebbing, and cell death via apoptosis [Kirson, 2007]. In
support of this hypothesis, microphotographic images of cells exposed to AEFs
demonstrate prolonged mitosis, nuclear rotation, and apoptotic cell death [Kirson, 2004;
Tuszynski, 2016; Wenger, 2016]. However, emerging evidence of differential expression
of voltage gated membrane channels, such as big potassium channels and pannexins, may
be implicated in apoptotic pathway initiation [Wei, 2015; Penuela, 2012].
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AEFs have now been translated into clinical use under the term Tumor Treating Fields
(TTFs). TTFs are low-intensity, intermediate-frequency, alternating electric fields
delivered across the entire cranium via external, scalp-mounted electrode arrays. A phase
III randomized clinical trial demonstrated the safety and efficacy of TTFs used during
maintenance treatment with TMZ following chemoradiation therapy for GBM. This
clinical trial treated patients with a maintenance therapy of TMZ (150-200 mg/m2/day) or
TMZ + TTFs delivered for 18 hours/day for 28 days via 4 transducer arrays placed onto
the shaved scalp connected to a portable pulse generator. Progression-free survival was
6.7 months in the TMZ + TTF versus 4 months in the TMZ alone group, and overall
survival was 20.9 months in the TMZ + TTF group versus 16 months for TMZ alone
[Stupp, 2017]. The results of this trial indicate the promise of TTFs in concert with
standardized GBM therapy. Patients who received TTFs demonstrated improved
cognitive and emotional function compared to those treated with chemotherapy and did
not display nausea, vomiting, fatigue, pain, and constipation [Lacouture, 2014]. This
novel treatment has been approved by the FDA for clinical use in the treatment of GBM
[Stupp, 2017; Rominiyi, 2021; Rehman, 2015; Sampson, 2015]. At the time of this
writing, TTFs are not approved by Health Canada and have not been widely implemented
into GBM treatment in North America. There remain many questions about the true
efficacy and utility in the clinical setting and several well-described shortcomings of
TTFs have been published are likely responsible for limited efficacy and both patient and
clinician acceptance of this technology to date [Wenger, 2018; Lacouturea, 2014; Mittal,
2017].

1.3 Intratumoral Modulation Therapy
It is clear that cancer cells are often highly sensitive to low intensity perturbations in the
electrical environment. However, the translation of this knowledge and approach to the
clinical care of brain cancer patients has presented a major challenge. In efforts to
maximize impact, safety and acceptance, our group has been pioneering the first brainimplantable, low intensity electric field cancer therapy, called Intratumoral Modulation
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Therapy (IMT). IMT is being developed with the premise that internalized electric fields
will exploit HGG electrosensitivity with fewer limitations than externally applied
delivery systems [Wenger, 2018; Lacouturea, 2014; Mittal, 2017]. Still in the proof-ofconcept stage, the vision of IMT encompasses the delivery of therapeutic electric fields
via MRI-compatible bioelectrodes strategically positioned within tumor-affected brain
regions. Compared to the externally delivered electric fields, IMT is delivered by
indwelling hardware that provides focused and titratable therapeutic electric fields
directly to CNS tumors and is not diminished by delivery through extra-cerebral tissues
such as the scalp, skull, meninges and uninvolved brain. A significant strength of IMT is
the ability to place the electrodes anywhere in the CNS, allowing for the effective capture
of infratentorial and brainstem disease which is inaccessible to scalp-mounted delivery
systems [Ghiaseddin, 2020]. In addition, the IMT system would be totally concealed to
provide continuous, perpetual therapy to treat unresectable tumors, residual tumors or
tumor resection beds to prevent recurrence. The hope is that IMT will attenuate tumor
growth, bolster multi-modality treatment platforms, and thereby improve patient
outcomes and quality of life.
Prior to my joining this project, the research team had already produced substantial proof
of concept data that demonstrated efficacy of IMT in vitro, with preferential impact on
GBM compared to non-neoplastic neural cells, and a significant improvement in
therapeutic impact when IMT was combined with chemotherapy or gene-targeting
approaches [Xu, 2016]. Our lab established an in vitro IMT model which delivered
continuous, low-frequency, low-intensity stimulation (130Hz, 4V) to GBM cell lines and
patient-derived GBM cells [Xu, 2016]. The model consisted of culture dishes fashioned
with clinical grade, platinum-based, reference strip electrodes (AD-Tech, Racine,
WI,USA) around the periphery and a central stimulating electrode (Medtronic Ltd.,
Brampton, ON, Canada). Cell monolayers were then seeded to the bottom of the well
and the electric fields were delivered by connecting the electrodes to a waveform
generator with the option to produce a myriad of stimulation parameters. IMT caused
significant cell death (>40%) in both human glioma LN229 cells and patient derived
GBM cells, without affecting the viability of post-mitotic neurons [Xu, 2016]. It was also
demonstrated that the mechanism of cell death by IMT was largely apoptotic. When IMT
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was applied with concomitant TMZ, GBM cell death increased to 70% compared to 30%
with TMZ alone. Finally, when IMT was administered in combination with siRNA
targeted to the pro-tumor chaperone, HSP27, uptake was increased and cell death
enhanced by 65% compared to 30% with HSP27 knockdown alone [Xu, 2016]. However,
the low-frequency stimulation settings used in these early studies mirrored those used in
clinical neuromodulation methods and were known to entrain neural systems [McCairn,
2015]. The research team raised concern that such settings would have a high chance of
creating off-target neural side effects when treating brain cancer and so sought alternative
parameters that would be out of the range of neural entrainment. It was at this point that I
joined the team and sought to contribute to the early development of exploratory studies
investigating the efficacy and delivery strategies for new IMT strategies.

1.4 Hypotheses and Objectives
My project took multiple facets that aimed at advancing our knowledge of IMT efficacy
and improved delivery strategies for HGG. At the outset of this thesis, the team had
confirmed GBM sensitivity to directly-applied, non-ablative electrical pulses, using lowfrequency (i.e., Hertz, Hz) stimulation that posed risk of neuronal entrainment and offtarget neurological side effects if applied within eloquent CNS areas. We hypothesized
that intermediate frequency (i.e., kHz) stimulation above the known neural entraining
range would provide a safe, effective niche for therapeutic development against GBM
while remaining inert to non-neoplastic cells. The objective of Chapter 2 was to
evaluate a novel profile of in vitro IMT parameters using intermediate-frequency (200
kHz) stimulation with a sinusoidal waveform to deliver continuous, low-intensity (±2 V),
alternating electric fields in order to provide maximal tumor cell disruption. Following in
vitro validation of intermediate-frequency IMT, the next step was to translate the
treatment paradigm in vivo; however, cancer models with implanted hardware for the
delivery of electric fields do not exist. We hypothesized that F98 tumors grown in
immunocompetent Fischer rats would be vulnerable to IMT delivered electric fields.
We aimed to develop and implement a completely novel IMT system in a syngeneic F98
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Fischer rat model. The results in Chapter 2 demonstrated the robust efficacy of IMT in
vitro and limited efficacy in vivo and prompted the exploration of IMT impact in
additional primary brain cancers in Chapter 3. We hypothesized that IMT electric fields
would provide an effective mean of disease control for DIPG and sensitize the cancer
cells to chemoradiotherapy. The objective of Chapter 3 was to determine the
vulnerability of patient-derived DIPG cells to low-intensity electric fields delivered using
our established IMT protocol. The impact of IMT on DIPG resistance to conventional
radiation and chemotherapy options was also investigated. To explain the limited efficacy
observed in vivo observed in Chapter 2, we initiated a collaboration with Dr. Eugene
Wong in the Department of Medical Biophysics to computationally investigate IMT
electric fields. These investigations revealed the inadequate distribution of IMT electric
fields using our single electrode delivery system that had been used so far in vitro and in
vivo. We also know that multiple electrodes are commonly implanted in standard
neurosurgical operations performed for movement disorders, epilepsy and pain
management. Our IMT data and the existing clinical experience in non-cancer therapies
led us to the hypothesis that multi-electrode IMT would maximize electric field
distribution across targeted tumor areas and provide a more appropriate platform to
develop translation models for HGG care. The objective in Chapter 4 was to develop
and validate a completely novel multiple electrode IMT system and validate the electric
field delivery and efficacy in customized 3-dimensional human GBM spheroid and
organoid preparations. I also had the privilege of comparing the impact of IMT, for the
first time, in primary GBM and normal brain organoids harvested directly for human
patients undergoing real-time neurosurgical procedures.
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Chapter 2

2

Preclinical Outcomes of Intratumoral Modulation
Therapy for Glioblastoma1

Glioblastoma (GBM) is the leading cause of high fatality cancer arising within the adult
brain. Electrotherapeutic approaches offer new promise for GBM treatment by exploiting
innate vulnerabilities of cancer cells to low intensity electric fields. This report describes
the preclinical outcomes of a novel electrotherapeutic strategy called Intratumoral
Modulation Therapy (IMT) that uses an implanted stimulation system to deliver
sustained, titratable, low intensity electric fields directly across GBM-affected brain
regions. This pilot technology was applied to in vitro and animal models demonstrating
significant and marked reduction in tumor cell viability and a cumulative impact of
concurrent IMT and chemotherapy in GBM. No off target neurological effects were
observed in treated subjects. Computational modeling predicted IMT field optimization
as a means to further bolster treatment efficacy. This sentinel study provides new support
for defining the potential of IMT strategies as part of a more effective multimodality
treatment platform for GBM.

2.1 Introduction
Glioblastoma (GBM) is the most common and aggressive primary brain cancer in adults,
affecting ~1 in 33,333 people annually and ending the life of an untreated patient within 3
months after diagnosis [Nam, 2016]. The current standard of care is surgical resection,
when possible, along with radiation and temozolomide (TMZ) chemotherapy.
_____________________
A version of this chapter is published as:
Andrew Deweyert*, Andrea R. DiSebastiano*, Simon Benoit, Erin Iredale, Hu Xu,
Cleusa De Oliveira, Eugene Wong, Susanne Schmid, Matthew O. Hebb. (2018).
Preclinical outcomes using direct-targeting Intratumoral Modulation Therapy for
glioblastoma. Scientific Reports. 8(1): 7301.
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Despite maximum available treatment, the cancer inevitably recurs and yields a median
survival of only 14 months [Nam, 2016]. There is now mounting evidence that
electrotherapy may offer new promise as an effective treatment modality much needed
for GBM patients [Mun, 2017]. The rationale for this strategy is based on an innate
sensitivity of GBM cells to non-ablative electric current or fields that are innocuous to
normal neural tissues, thus creating a putative safety margin for therapeutic development
[Xu, 2016; Kirson, 2004]. Such low intensity electrotherapy likely works through
multiple mechanisms that relate, in part, to disruption of polarized cellular elements
necessary for cytokinesis as well as changes in membrane permeability and channel
homeostasis [Pawlowski, 1993; Gera, 2015]. There is presently a single electrotherapy
approved for GBM in the United States. This system includes a portable electric field
generator to deliver low intensity (1–3 V/Cm), intermediate frequency (200 kHz)
alternating electric fields, called tumor treating fields (TTFs), to supratentorial brain
regions. TTFs are administered through arrays of insulated electrodes adhered to the
patient’s scalp [Hottinger, 2016]. Continuous, long-term application is recommended,
and the transducer arrays are replaced every few days. The clinical impact of TTFs in
GBM has been evaluated in two randomized, multi-centre trials [Stupp, 2012; Stupp,
2017]. The studies had methodological constraints but produced results supporting a
significant clinical benefit in both recurrent and newly diagnosed disease. Potential
drawbacks of TTF therapy include the need for a shaved head, frequent electrode
changes, scalp complications from chronic electrode wear, stigmata of an external
treatment device, inability to target infratentorial or spinal disease and high treatmentrelated costs [Sampson, 2015; Mittal, 2017].
The most common (>90%) pattern of GBM progression occurs as aggressive, continuous
extension from the site of the original lesion [Gaspar , 1992; Halperin, 1988; Lee , 1999;
Loeffler, 1990]. This important recognition has led to decades of research attempting to
develop effective locoregional strategies to control growth of inoperable tumors and
prevent recurrence following surgical resection [Ashby , 2016; Barbarite, 2017; de Paula,
2017; Hersh, 2016]. Our group has been pioneering a novel locoregional electrotherapy,
called Intratumoral Modulation Therapy (IMT), with the premise that an internalized
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electric field will exploit GBM electrosensitivity to greater advantage and with fewer
limitations than an externally applied (e.g., scalp-mounted) source [Xu, 2016].
Still in the proof-of-concept stage, the clinical vision of IMT uses special purpose,
magnetic resonance imaging (MRI)-compatible bioelectrodes strategically positioned
within, or adjacent, tumor-affected regions of the central nervous system (CNS). A key
feature of IMT is the ability to reach any aspect of the CNS to provide focused, titratable
therapy directly within areas of disease. Bioelectrodes could be designed for personalized
and comprehensive treatment coverage of GBM resection beds or non-operated lesions
within eloquent or deep-seated CNS regions. The proximity of the IMT field source to
GBM pathology will permit a broad, versatile spectrum of stimulation parameters custom
optimized to tumor location and treatment response. Such a concealed, indwelling system
is expected to support patient quality of life while providing sustained, low maintenance
therapy that potently complements radiation and ongoing chemotherapeutic options.
We recently described an in vitro IMT approach using monophasic, low amplitude (4 V),
low frequency (130 Hz) square wave pulses that induced apoptosis in patient GBM cells
without notable impact on primary neurons [Xu, 2016]. Adjuvant IMT significantly
increased GBM cell death when combined with TMZ or oncogene-targeting therapies
[Xu, 2016]. These early results confirmed GBM sensitivity to directly applied, nonablative electrical pulses but the low frequency parameters posed risk of neuronal
entrainment and off-target neurological effects if applied within eloquent CNS areas
[Palti, 1996]. The objective of the present study was to evaluate a novel profile of IMT
parameters using intermediate frequency (200 kHz) stimulation with low risk of neuronal
entrainment and a sinusoidal waveform to deliver continuous, alternating polarity, low
intensity (±2 V) electric fields. These new parameters were first validated using our
established in vitro methods then translated to test IMT for the first time in a customized
in vivo GBM model.
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2.2 Materials and Methods
2.2.1

GBM cell cultures

These protocols were approved by the Human Research Ethics Board and the Animal
Care Committee at Western University and carried out in accordance with the TriCouncil Policy for research involving human subjects and the Canadian Council on
Animal Care. Informed consent was obtained from all patients or their legal guardians
prior to using their GBM tissue in this study. Human GBM cells were isolated from
operative tumor specimens obtained from 3 patients (39 y male, 44 y female, 65 y
female). Specimens were not genetically screened for study purposes. The tumor samples
were collected into phosphate-buffered saline (PBS) with 0.5% fetal bovine serum (FBS;
Life Technologies) at the time of surgery. The tissue was digested and filtered then
suspended in Dulbecco’s modified Eagle’s medium (DMEM; Wisent Bioproducts)
supplemented

with

10%

FBS,

1%

non-essential

amino

acids

and

1%

penicillin/streptomycin (Life Technologies). Homogenates were plated on a 35 mm dish
for 30 minutes to allow for separation of blood cells. The upper cell suspension was then
transferred to two wells of a 24-well plate, freshly pre-coated with 10 μg/ml poly-Llysine (Trevigen Inc) and incubated at 37 °C with 5% CO2. Cultures were passaged at
approximately 80% confluence and split 1:2 using 0.25% trypsin with 0.53 mM
ethylenediaminetetraacetic acid (EDTA; Wisent). The medium was changed twice per
week. All assays were conducted using GBM cells from cultures at passages 4 through
12.
The F98 GBM cell line (CRL2397TM; ATCC) was originally created following a single
N-ethyl-N-nitrosourea injection to a pregnant Fischer rat to produce offspring with
malignant glioma tumors that were then maintained in culture [Mathieu, 2004; Mathieu,
2007]. The low immunogenicity of F98 cells in syngeneic Fischer rats offers advantages
over xenogeneic and allogeneic models that require immunosuppression or may exhibit
spontaneous tumor regression. F98 GBM tumors are highly proliferative, invasive, and
recalcitrant to conventional therapies, closely mimicking the human disease. F98 cells
were cultured in 100 mm dishes in DMEM supplemented with 10% FBS, 1% nonessential amino acids and 1% penicillin/streptomycin (Life Technologies) in a humidified

29

incubator at 37 °C with 5% CO2. The medium was changed twice per week and cultures
passaged at ~80% confluence and split 1:2 using 0.25% trypsin with 0.53 mM EDTA
(Wisent).

2.2.2

Primary neuronal cultures.

IMT was evaluated in post-mitotic primary neurons isolated from embryonic rat brains
(N = 3). Cerebral cortices from E18 Wistar embryo were dissected into a 14 ml conical
tube containing 1.8 ml of Hank’s balanced salt solution (HBSS; Wisent) and centrifuged
at 4000 × g for 1 min at room temperature. HBSS was aspirated and 1.8 ml of solution A
containing 5 ml HBSS, 6 μl MgSO4 (1 M) and 2 ml trypsin (Sigma Aldrich) were added.
The tube was mixed well and placed in an automated rotator at 37 °C for 25 minutes.
After rotation, 3.6 ml of solution B containing 7 ml HBSS, 8 μl MgSO4 (1 M), 175 μl
DNase1 (10 mg/ml) and 112 μl trypsin inhibitor (100 μg/ml; Roche Life Sciences) were
added and mixed for 2 minutes, centrifuged at 4000 × g for 5 min at room temperature,
and then the HBSS was aspirated. Finally, 6 ml of solution C containing 20 ml of HBSS,
48 μl MgSO4 (1 M), 1.3 ml DNase1 (10 mg/ml), and 1 ml trypsin inhibitor (100 μg/ml)
were added to the resulting cell pellet (Roche). These cells were transferred to a 50 ml
falcon tube and another 6 ml of solution C was added. The cells were titrated, centrifuged
at 4000 × g for 5 minutes and the supernatant aspirated. The cell pellet was re-suspended
in 36 ml of media containing 96% neural basal media (Wisent), 2% B27 supplement,
0.8%

N2

Supplement,

0.5%

penicillin/streptomycin,

0.25%

Glutamax

(Life

Technologies), and 0.1% Amphotericin B solution (Sigma Aldrich). Cells were counted
with a hemocytometer, plated in 35 mm wells coated with 7% poly-L-Ornithine (Sigma
Aldrich) at density of 0.5 × 106 cells/well and kept in a humidified incubator at 37 °C
with 5% CO2. On the third day of culture, the media was changed, and wells were fitted
with the IMT apparatus for delivery of 72 h of sham or IMT conditions.

2.2.3

In vitro IMT model

The impact of IMT alone and combined with TMZ was independently evaluated in
triplicate using primary human GBM cells, rodent F98 GBM cells and post-mitotic
rodent primary neurons. GBM cells and primary neurons (1–5 × 105 cells) were cultured
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in 35 mm wells in standard 6-well plates. GBM cells were grown to ~70% confluence
before treatment. The IMT model was created by fitting each well with a clinical grade,
platinum-based strip bioelectrode (AD-Tech) around the periphery and a single contact
platinum-iridium bioelectrode (Medtronic Ltd.) at the center of the well and cell culture
[Xu, 2016]. A waveform generator (Rigol DG1022; Electro-Meters Ltd.) was used to
deliver biphasic sinusoidal pulses with low amplitude (+ /−2 V; peak-to-peak 4 V) and
intermediate frequency (200 kHz) for a period of 72 hours. Control wells (i.e. shamtreated) were fitted with electrodes but no current was delivered. GBM cells treated with
chemotherapy were plated with DMEM containing TMZ (50 μM; Sigma Aldrich) and
received 72 hours of concomitant IMT or sham conditions. This TMZ concentration
reflects clinically relevant levels corresponding to the in vivo plasma concentration of 150
mg/m2 in the adjuvant phase of GBM treatment [Ostermann, 2004].

2.2.4
Cell

Cell viability assays
viability

was

evaluated

using

the

3-(4,5-dimethylthiazol-2-yl)-2,5-

diphenyltetrazolium (MTT) spectral analysis (Sigma Aldrich). This spectrophotometric
assay measures the reduction of yellow MTT by mitochondrial succinate dehydrogenase
to an insoluble, dark purple Formosan product. Immediately following the GBM cell
treatments described above, MTT (80 μl at 5 mg/ml) was added to the 35 mm wells and
incubated for 3 hours at 37 °C in a humidified 5% CO2 atmosphere. The cells were then
lysed to release the purple Formosan product by the addition of 600 μl dimethyl sulfoxide
for 15 minutes at room temperature. Absorbance was measured using an enzyme-linked
immunosorbent assay plate reader (Fisher Scientific). Cell viability was estimated using
optical density values at 570 nm with references at 655 nm detected in each well.
Trypan blue exclusion was used as a confirmatory, qualitative measure of cell viability.
Briefly, 0.1 ml of a 0.4% trypan blue solution (Lonza) was added for every 1 ml culture
media and the cells incubated for 2 minutes at room temperature. Brightfield images of
cells stained with MTT and trypan blue were obtained using a Motic AE31 inverted
microscope fitted with an Infinity 1–3 scientific complementary metal-oxide
semiconductor camera (Lumenera Corp).
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An Annexin V Apoptosis Detection Kit with propidium iodide (PI; BioLegend) was used
to quantify live, apoptotic, and dead GBM cell fractions, as per the manufacturer’s
instructions. Cell fractions were analyzed using a Becton Dickinson LSR II SORP flow
cytometer running FACSDiva software (BD Biosciences). Cells were first gated on
forward scatter (FSC−) versus side scatter (SSC−) characteristics before excluding
doublets using consecutive gating FSC-Area versus FSC-Width and SSC-Area versus
SSC-Width plots. The populations of annexin V+/PI−, annexin V+/PI+, annexin V−/PI+
and annexin V−/PI− were then calculated with quadrant gates. Approximately 15,000–
30,000 single GBM cells were acquired per each of three patient samples at a maximum
event rate of 5,000 events per second. Data were analyzed using FlowJo v 9.6.3
(TreeStar, Inc).

2.2.5

In vivo GBM model and IMT

Bilateral orthotopic GBM tumors were established by implanting F98 cells into the brain
of syngeneic adult female Fischer rats (Charles River) [Mathieu, 2004; Mathieu, 2007]. A
cohort size of 25 was chosen to adequately temper inter-animal variability and account
for unexpected problems or deaths. Subjects were maintained under isoflurane anesthesia
for stereotactic implantation of chronic cannula-bioelectrode constructs (Plastics One)
into bilateral striata (coordinates from bregma: anteroposterior 1 mm, lateral +/−3 mm,
dorsoventral −6 mm). The constructs consisted of a 5 mm long steel cannula with 1 mm
luminal diameter, running parallel to a 6-mm-long, rigid lead with a 1 mm long, 0.25 mm
diameter bioelectrode contact at the distal tip. The reference bioelectrode was connected
by a flexible 1 cm long insulated wire and positioned extracranially in the temporal or
nuchal soft tissues. These three components were secured at a common, accessible
pedestal cemented to the skull. A key advantage of this cannula-bioelectrode construct
was the ability to implant GBM cells that form a large tumor mass centered around the
IMT bioelectrode within the brain. In two animals (#10, 11), the bioelectrode contact was
insulated with a thin layer of Entellan (Sigma Aldrich) prior to implantation. This pilot
modification was intended to assess the anti-GBM effect of an intratumoral electric field
without current flowing between the bioelectrodes and tissue.
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F98 GBM cells (4 × 104 in 2 μl DMEM) were delivered bilaterally through the implanted
cannulae, after which the pedestal was covered with a protective cap. Two operators were
present for quality assurance in all surgeries. On postoperative day 4, IMT was
randomized to the right or left tumor and the respective bioelectrode was connected to a
waveform generator (Rigol DG1022; Electro-Meters Ltd) via an extension cable and a
commutator that permitted the animal to move freely throughout the home cage. The
contralateral tumor served as an internal sham control (i.e., identical tumor and hardware
implants but without stimulation). Continuous IMT monotherapy was delivered between
postoperative days 4–11 using the in vitro parameters (i.e., sinusoidal waveform, +/−2V,
200 kHz). Three control subjects received bilateral hardware without GBM cell delivery
to assess potential adverse effects of IMT on normal brain structure. Five subjects had
unilateral implantation of GBM cells, as described above, using a Hamilton syringe and
without IMT hardware. Four of these subjects were used to assess GBM size after 4 days
of growth (i.e., the size at the onset of IMT). One animal underwent MRI on
postoperative day 7 as part of the simulation studies, described below. All animals were
given free access to food and water, perioperative antibiotics, and analgesics, and
monitored daily for medical or neurological complications. On post-operative day 11,
animals were deeply anesthetized with sodium pentobarbital and transcardially perfused
with 4% paraformaldehyde. The brains were extracted, cryoprotected and frozen. Brains
were cut into 16–35 μm thick sections through the rostrocaudal extent of the tumors,
mounted onto microscope slides and stained with thionine. Processed sections were
digitally imaged with a Nikon Eclipse Ni-E microscope.

2.2.6

GBM tumor analysis

Digitized brain images were imported into ImageJ v.2.0.0 software for tumor
measurement by a blinded observer. The wand tracing tool was used to select the GBM
tissue from surrounding brain with identical tolerance detection settings for the IMT- and
sham-treated tumors. Tolerance detection ranged from 10–40 pixels in 8-connected mode
and was adjusted accordingly between serial sections for variations in staining intensity.
Cross-sectional areas in serial sections were quantified in pixels and summed to provide
relative estimates of tumor volume. The whole tumor was measured using serial sections
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through the rostrocaudal extent of the GBM. A more focused measure of the tumor ‘core’
was calculated to assess the impact of IMT in the region of highest GBM burden (i.e., at
the implantation site) and anticipated center of the IMT electric field. This core region
was objectively defined within 4 brain sections containing the largest cross-sectional area
of both sham- and IMT-treated tumors in addition to the two immediately flanking
sections.

2.2.7

IMT electric field simulation

The IMT electric field created by the treatment parameters used in this study was
simulated based on 9.4 T MRI data from a representative control animal with a unilateral
7-day GBM, as described above. Imaging at this time point depicts the tumor size
midway through the treatment period (i.e., day 4–11). MRI data was imported to
Brainsuite v.16a1 for segmentation of the GBM tumor mass, associate cerebral edema,
whole brain and skull. Segmented volumes were then imported to Multiphysics v.5.2a
(COMSOL Inc.) where the intratumoral bioelectrode, reference bioelectrode and cannula
geometry was simulated according to the in vivo IMT paradigm. The bioelectrode was
modeled with stainless steel insulated with a 0.025 mm thick layer of polyimide except
for the distal tip where a 1 mm contact was exposed. The conductance and dielectric
properties of the segmented brain tissues, skull and bioelectrode apparatus were then
specified within the COMSOL Electric Currents user interface which was employed to
compute the electric field [Wenger, 2015; Wenger, 2016]. A constant voltage of 2.0 V at
200 kHz was applied across the intratumoral and reference bioelectrodes within this
computer model. The resulting map of the electric field amplitude was exported and
merged with the MR images for visualization in 3D Slicer v.4.4.0. The dimensions and
amplitude of the electric field within the tumor and brain were analyzed using MATLAB
R2015b (MathWorks Inc).

2.2.8

Magnetic resonance imaging

MRI studies were performed at The Centre for Functional and Metabolic Mapping,
Robarts Research Institute, Western University. An Agilent small animal 9.4 T MRI unit
was used to obtain true fast imaging with steady state precession (TrueFISP; TR = 7 ms,
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TE = 3.5 ms, flip angle = 30 degrees, number of frequencies = 4, number of averages = 4,
total acquisition time = 42 minutes, field of view=28mm×28mm×28mm, acquisition
matrix=140×140×140).

2.2.9

Statistical analysis

A t-test or Wilcoxon signed-rank test was used to compare single and paired in vitro data
sets that followed or deviated from a normal distribution, respectively. Multiple pairwise
comparisons were performed using one-way analysis of variance (ANOVA) followed by
Tukey post-hoc analysis. In vivo tumor measures were evaluated using the Dixon’s and
Grubb’s tests for outliers. The in vivo IMT response was assessed by calculating the
percent change in tumor volume for each subject and using a single sample t-test to
compare the cohort values to a hypothetical mean change of zero percent. A
complementary analysis did not assume uniform untreated rates of growth amongst
tumors and compared the cumulative GBM burden following sham and IMT treatment
within the entire cohort using a paired sample t-test. One-tailed analyses were used for
statistical comparisons based on the known in vitro efficacy of IMT against GBM [Xu,
2016]. Statistical software used included Sigma Stat (Systat Software Inc) and SPSS v
14.0 (IBM). Data are presented as mean ± standard deviation with significance assumed
at p < 0.05. Data availability. All data analyzed during this study are included in this
published article.

2.3 Results
2.3.1

Intermediate frequency IMT selectively kills GBM
cells and provides cumulative anti-neoplastic effects
when administered with TMZ chemotherapy

The MTT assay generated spectrophotometric values that reflected cell viability. Results
of each treatment condition were normalized to those of the sham group. GBM cells from
3 patient tumors were independently treated and the data pooled for analysis. The
individual MTT values are provided in Table 2.1. TMZ produced a modest but significant
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reduction in patient GBM cell viability to 82.6 ± 3.0% (P = 0.001), whereas IMT resulted
in a greater drop to 65.1 ± 4.0% (P < 0.001) of sham values. Co-administration of TMZ
with IMT resulted in a dramatic cumulative loss of GBM cell viability to 45.8 ± 4.0% (P
< 0.001) of sham values (Fig. 2.1). The difference in GBM cell viability between TMZ
and IMT (P < 0.001), and between TMZ (P < 0.001) or IMT (P < 0.001) and the
combined TMZ + IMT treatments were all highly significant. The F98 GBM cells were
similarly vulnerable to IMT, with a reduction to 54.9 ± 6.3% (N = 3; P = 0.008) of sham
values. In contrast, primary neuronal cultures did not exhibit obvious changes in
morphology nor were the MTT measures notably affected by IMT, with a mean group
viability of 105.5±5.3% (N=4; P = 0.091) of sham values (Fig. 2.1).
Table 2-1. Spectrophotometric viability (MTT) analysis in patient GBM cells

Shown are the MTT values, normalized to the respective sham control, for GBM cells
obtained from 3 patients. Cells were exposed to the indicated conditions for 3 days
preceding analysis. IMT was statistically superior to temozolomide in reducing GBM cell
viability and the combination of temozolomide and IMT produced dramatic, highly
significant anti-neoplastic effects. These data are summarized in Fig. 2.1.
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Figure 2-1. Impact of intermediate frequency IMT on GBM cells in vitro.
Brightfield photomicrographs of patient and rodent F98 GBM cells and primary neurons
are shown following a 3-day exposure to the indicated treatments. The images captured
cell fields adjacent to the bioelectrode implanted within the cultures (not shown). (A)
Patient GBM cells stained with the dark MTT chromogen demonstrate robust viability
under sham conditions. A moderate reduction in staining, accompanied by pyknosis and
decreased cell density was observed with (B) TMZ or (C) IMT monotherapy. (D)
Concomitant TMZ+IMT resulted in a dramatic loss of cell viability compared to that
achieved with either treatment alone. (E, F) Susceptibility to the same stimulation
parameters was also evident in rodent F98 GBM cells as shown by MTT staining. (G, H)
In contrast, the morphology and density of post-mitotic primary neuronal cultures, as
shown here following trypan blue exposure, was not notably affected by IMT. (I) The
viability of GBM cells from 3 different patient tumors was significantly reduced by TMZ
or IMT alone. A cumulative GBM cell loss was produced by the combination of both
treatments, likely reflective of distinct mechanisms of action. Asterisks directly above the
data bars indicate a significant (P < 0.001) difference from the sham control. The
significance (P < 0.001) between indicated data pairs is depicted by an asterisk above the
horizontal lines. (J) F98 GBM (N = 3; P = 0.008) but not (K) primary post-mitotic
neuronal (N = 4; P = 0.091) cultures were susceptible to IMT. Asterisks directly above
the data bars indicate a significant difference from the sham control. All data are
presented as mean ± standard deviation
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Flow cytometry with Annexin V and PI labeling permitted quantification of live,
apoptotic, and dead GBM cell fractions. Primary neurons were not able to withstand the
flow cytometry methods. The assay was conducted on 15–30,000 GBM cells for each
treatment condition using biological replicates from 3 patients. The values for apoptotic
and dead cells were combined into a single category. The flow cytometry revealed 15.1 ±
12.2% apoptotic/dead GBM cells in the sham group compared with a progressive
increase in this fraction following treatment with TMZ (28.2 ± 7.1%; P = 0.488), IMT
(38.8 ± 6.0%; P = 0.032) and the combination TMZ + IMT (73.7 ± 2.1%; P < 0.001; Fig.
2.2; Table 2.2).

Figure 2-2. Flow cytometry measures of IMT response in patient GBM cells.
(A) Representative scatterplots of annexin and propidium iodide (PI) labeling of
apoptotic and dead patient GBM cells, respectively, after a 3-day exposure to the
indicated treatment. IMT produced a greater cytotoxic effect than TMZ but the number of
apoptotic and dead GBM cells rose dramatically with combined therapy. (B) Quantitative
flow cytometry revealed a significant difference (P < 0.001) between live and
apoptotic/dead fractions within each of the sham, TMZ and TMZ+IMT groups, but not in
the IMT group (P = 0.053). This corresponded to a significant loss of GBM cell viability
with IMT, but not TMZ, and a cumulative increase in cytotoxicity with the combination
of the two treatments. These studies were performed in triplicate using primary GBM
cells from 3 different patients. Asterisks directly above the data bars indicate a significant
difference from the respective sham value (e.g., live compared to live). Significance
between indicated data pairs is depicted by the asterisk(s) above the horizontal lines. Data
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are presented as mean ± standard deviation with significance indicated at P *< 0.05, **<
0.01 and ***< 0.001.

Table 2-2. Individual flow cytometry measures of IMT response in patient GBM
cells.

Shown are the percentages (%) of live (Annexin−/PI−) versus apoptotic (Annexin+/PI−)
or dead (Annexin+/PI+) patient GBM cells quantified with flow cytometry. Each
condition was evaluated in 3 biological replicates with 15,000–30,000 patient GBM cells
exposed to the indicated treatment for 3 days. The differences in therapeutic impact
between groups were highly significant and are summarized in Fig. 2.2.

2.3.2

IMT significantly attenuates GBM growth in vivo

The syngeneic rodent F98 GBM model was customized to evaluate IMT efficacy against
GBM in the living brain (Fig. 2.3A–C). The treatment period spanned post-operative
days 4–11 during which no neurological, behavioral or pain symptoms related to the
stimulation were observed. Of the original 25-animal cohort, 15 animals were included in
the final analysis. The excluded animals were: 4 with evidence of overt infection
extending into the brain, 1 with insufficient tumor take, 3 with incomplete histological
preparations and 2 that expired from undetermined causes. The first death occurred on
postoperative day 3, prior to initiating IMT. The second death occurred 3 days after IMT
initiation. The brain of this animal was examined histologically and no evidence of
treatment-related complication (e.g., electrolysis, hematoma) was identified. In addition
to the 25-animal cohort, control animals with unilateral tumor-only implants (N = 4)
evaluated on postoperative day 4 (i.e., the time point of IMT initiation) revealed the
expected GBM growth consistent across the group (Fig. 2.3D). Animals that received
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IMT and sham treatments without previous GBM implants (N = 3) revealed no obvious
stimulation-related injury to normal brain parenchyma (Fig. 2.3E).

Figure 2-3. In vivo model to evaluate IMT in GBM.
In vivo model to evaluate IMT in GBM. (A) Schematic and (B) photographic depiction of
the in vivo IMT model. The animals could roam freely throughout the home cage.
Bilateral GBM tumors were randomized so that one would receive sham treatment (i.e.,
hardware but no stimulation) and the other IMT between postoperative days 4–11. This
provided an internal control tumor for every subject. (C) The IMT construct consisted of
a lead with a single 1-mm stimulating bioelectrode, a cannula to deliver the GBM cells
and a reference bioelectrode. The stimulating bioelectrode was located at the core of the
GBM tumors and the reference bioelectrode positioned extracranially under the scalp. (D)
Representative thionine-stained section of a control brain demonstrating a 4-day GBM,
reflecting the tumor size when IMT was initiated (arrow). (E) Representative thioninestained section through another control brain to show the effects of IMT on normal
parenchyma. There was no tumor in this subject however bilateral IMT constructs were
placed for delivery of 1 week of sham (left) or IMT (right). Symmetric hardware defects
were evident (asterisks) without overt parenchymal injury from the stimulation.

The bilateral GBM tumors were randomized to sham treatment or IMT, with 8 right- and
7 left-sided tumors receiving IMT by the end of the study. GBM tumors that received
IMT were typically more rounded and compact compared to the oblong, irregular
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configuration of sham-treated lesions. GBM volumes were estimated through the
rostrocaudal extent of the tumor (‘whole tumor’) and within a core region at the
presumed centre of the IMT electric field (‘core tumor’). The whole tumor measures
revealed smaller IMT-treated, compared to sham-treated, tumors in 11/15 (73%) animals.
There was a single, statistically-proven outlier (subject #7) in which the discrepancy
between IMT- and sham–treated tumors was drastically reversed. The reason for this
finding was not identified, however hypothesized to be technical in origin, such as a
problem with the GBM implant or the laterality marker. The change in tumor volume for
this animal fell well past 2 standard deviations from the mean (i.e., >95th %-tile of the
normal data distribution) and was identified by both the Dixon’s (P = 0.028) and Grubb’s
(P = 0.016) tests as a significant outlier. The statistical evidence supported its exclusion;
however, the cumulative GBM measures for the entire cohort were calculated both in the
presence and absence of the outlier subject (Figs. 2.4 and 2.5). With the outlier included,
there was a non-significant 14.5% reduction in IMT-treated whole tumor volume (P =
0.107) that rose to a significant 19.5% reduction (P = 0.047) with the outlier excluded
(Table 2.3). The percent change in the IMT tumor volume relative to that of the sham
tumor was also calculated in each subject and averaged over the cohort. These data
aligned with the cumulative tumor measure analysis and showed that with inclusion of
the outlier, IMT produced a whole tumor reduction of 12.7 +/− 35.8% (P = 0.096). With
subject #7 excluded, the volume reduction of the IMT-treated GBM increased to a highly
significant 19.7 +/− 24.3% (P = 0.005).
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Figure 2-4. IMT attenuates locoregional GBM growth in vivo.
(A) Representative, thionine-stained brain sections from 6 animals with GBM treated
throughout this study. The 7-day course of IMT was randomized to the right or left GBM
(treatment sides have been aligned in this figure for comparative purposes), with the
contralateral tumor used as a sham control. The subject identifier is shown to the upper
left of each section. GBM volumes were estimated by cumulative cross-sectional tumor
areas quantified using ImageJ software, as demonstrated by the yellow tracing in subject
9. (B) The difference in estimated whole (i) and core (ii) GBM volume following IMT,
relative to the internal sham control, is provided for every animal. Negative values are
consistent with treatment response. The whole tumor measures incorporate serial sections
through the rostrocaudal extent of the GBM whereas the core tumor measures were
limited to the region surrounding the bioelectrode. There was one outlier (#7, shown in
gray) with a reversal of expected effects, presumed technical in origin. (C) Distribution
plots showing volume differences in the IMT-treated i) whole and ii) core tumor over
10% intervals. For example, a data bar on the −50% tick mark depicts the number of
animals that had a 50–60% tumor reduction. The solid black-to-white lines indicate the
cohort means when the data included the outlier shown in gray. The dashed lines indicate
the standard deviation of this mean. Note that the outlier is well beyond 2 standard
deviations of the mean. The red lines depict the cohort means with the outlier excluded.
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Figure 2-5. Paired in vivo GBM responses to sham and IMT conditions.
Raw tumor measures calculated from the (A) whole tumor and (B) core tumor are shown
after sham treatment (black) or IMT (white). The statistical outlier shown in Fig. 4 has
been left in this dataset for completion (subject #7; labeled O). The IMT-treated GBM
was smaller than the sham-treated tumor in 11 of 15 (73%) and 12 of 15 (80%) subjects
using whole and core tumor measures, respectively.

43

Table 2-3 Cumulative in vivo tumor burden in sham and IMT-treated GBM within
the 15-animal cohort.

Core tumor analysis focused on the GBM region nearest the bioelectrode and identified
12/15 (80%) animals with smaller IMT-treated, compared to sham-treated, core tumors.
Subject #7 was again identified as a statistical outlier using the Dixon’s (P = 0.004) and
Grubb’s (P = 0.002) tests. Cumulative core GBM burden for the whole group was 19.7–
23.7% smaller in IMT tumors compared to sham controls, a highly significant response
regardless of the outlier measure (Table 2.3). There was also a significant mean
individual reduction of 15.8 +/− 32.0% (P = 0.038) when assessed with the outlier
included. This measure rose to 22.7 +/− 18.3% (P = 0.0002) with the outlier excluded.

2.3.3

Computer simulation predicts IMT electric field
properties in GBM tumor and brain

These studies sought to define the extent of in vivo treatment coverage produced within
the GBM environment using the present IMT hardware and stimulation parameters. IMT
electric field modeling was performed in a representative 7-day rodent GBM to best
estimate the tumor size and brain conditions at the mid-way point of the current IMT
protocol which extended between days 4–11 following GBM cell implantation. The
simulation analysis demonstrated a tightly constrained electric field centered near the
core of the GBM mass with radial extension to a modest fraction of the tumor and
surrounding edematous brain (Fig. 2.6). The amplitude of the IMT electric field
decreased logarithmically with the radial distance from the bioelectrode. Field strengths
of 4 V/cm, 3 V/cm, 2 V/ cm and 1 V/cm extended to 0.32 mm, 0.43 mm, 0.63 mm, 1.24
mm, respectively, from the source. It was estimated that the fractions of GBM tumor that
received an IMT electric field amplitude above these thresholds were 3.0%, 4.8%, 9.5%
and 24.2% respectively. When combining the regions of GBM tumor and associated
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edematous brain, the fractions predicted to receive these field thresholds were 0.5%,
1.0%, 2.4% and 12.1%, respectively (Fig. 2.7).

Figure 2-6. Image-based simulation of IMT electric fields.
A 9.4T MRI system was used to generate true fast imaging with steady state precession
(TrueFISP) images of a 7-day GBM tumor in the rodent brain. Coronal (A,B) and sagittal
(D,E) images are shown. (A,D) Brainsuite software (v.16a1) was used to segment the
tumor (yellow trace) and edema (turquoise trace). The segmented volumes were imported
to COMSOL Multiphysics (v.5.2a), where the intratumoral bioelectrode and cannula
geometries were simulated. (B,E) The conductance and dielectric values of the hardware
(bioelectrode, black arrow; cannula, white arrow) and neural elements were used with the
boundary condition of constant voltage amplitude of 2.0 V at 200 kHz for the
bioelectrode and the reference electrode applied outside the skull. The resulting map of
the electric field magnitude was exported and combined with the TrueFISP MR images
for visualization in 3D Slicer (v.4.4.0). The electric field data within the tumor was
analyzed using MATLAB R2015b to estimate the fraction of tumor receiving specific
field amplitudes (see Fig. 7). Three-dimensional rendering of the rodent brain shown in
(C) coronal and (F) oblique sagittal views depict the relationship between the 1)
intratumoral bioelectrode, 2) cannula, 3) GBM mass and 4) region of tumor-associated
cerebral edema. S, superior; I, inferior; M, medial; L, lateral; A, anterior; P, posterior.
The scale bar in B corresponds to panels A and B; that in E to panels D and E; both
depict 5 mm.
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Figure 2-7. Predicted relations between IMT electric field amplitude, radial field
dimensions and extent of GBM region coverage in the present in vivo treatment
model.

2.4 Discussion
This preclinical study is, to our knowledge, the first to demonstrate the efficacy of an
implantable electrotherapy using non-ablative, intermediate frequency stimulation in
patient-derived GBM cells and in a cohort of living animals with intracerebral GBM.
Primary GBM cells, but not neurons, were exquisitely sensitive to low amplitude,
sinusoidal pulses at a frequency out of range for neuronal entrainment or thermal injury
[Palti, 1996; Storm, 1982]. IMT-mediated cytotoxicity was largely apoptotic and
enhanced GBM cell death when co-administered with TMZ chemotherapy. This in vitro
proof-of-concept was translated to an animal model in which a 1-week course of
continuous IMT monotherapy produced a significant reduction of mean GBM volume in
the living brain. These highly promising data likely do not reflect the full potential of
IMT. There are technical and biological aspects of the present in vivo model which may
have led to an underestimation of therapeutic efficacy. For example, the rudimentary,
single-contact bioelectrode and applied stimulation parameters were predicted to generate
an IMT electric field ≥1 V/cm (i.e., the lower threshold recommended for the external
TTF device) throughout only ~24% of the estimated volume of a 7-day tumor [Mittal,
2017]. The compact IMT field dimensions (i.e., ~1.24 mm radius for a ≥1 V/cm field)
would poorly accommodate a suboptimally positioned bioelectrode, particularly if
located near or beyond the GBM boundary, which may explain the inter-animal
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variability in treatment response. The measured therapeutic impact, while significant, was
likely less than what may be achieved using hardware and stimulation parameters that
provide comprehensive coverage of the tumor-affected region. The large GBM burden in
the F98 model also created a greater treatment challenge than would be expected with
small volume or recurrent/residual tumors. In our hands, a deposit of 40,000 F98 cells
produced robust growth, expanding into moderate-sized lesions as early as day 4 and
massive GBM tumors with cerebral edema and central necrosis by day 11 postimplantation. Others have reported a mean survival between 18–25 days in rats harboring
these GBM tumors [Mathieu, 2005; Mathieu, 2007]. Anecdotally, the rate of growth may
be proportionally greater than typical for GBM in humans, creating a highly formidable
model in which to evaluate a putative new therapeutic device.
The development of an indwelling electrotherapy for GBM is predicated on a global
experience using deep brain stimulation (DBS) devices engineered to treat nononcological conditions, such as movement, pain, psychiatric and seizure disorders
[Udupa, 2015; Wichmann, 2016]. DBS entails stereotactic placement of in-line, multicontact leads into target brain regions, controlled by a remote-accessed, implantable pulse
generator. This technology typically delivers continuous, monophasic, square wave
pulses at low amplitude (e.g., 1–5 V) and frequency (e.g., 90–185 Hz) to disrupt and
entrain pathological firing patterns in a reversible, non-injurious manner [Herrington,
2016]. DBS and IMT are starkly different in indication, operational parameters, and
hardware design. The electrical output of prospective IMT systems will be defined by
non-ablative pulses coupled to customized and distinct profiles of waveform, polarity,
and frequency parameters titrated to individual tumor response and location. This study
utilized a low amplitude (+/−2 V), intermediate frequency (200 kHz), sinusoidal
waveform with reversing polarity intended to maximally disrupt electrical homeostasis in
GBM cells. The pulse frequency was 1000-fold higher than typical for DBS and well
beyond the range of neuronal entrainment so not to incite adverse neurological effects
when stimulating tumor-infiltrated CNS regions. This amplitude and frequency are also
below the threshold for producing thermal injury and have been shown to selectively
target GBM cells with relative safety in preclinical studies and human TTF therapy [Xu,
2016; Kirson, 2004; Hottinger, 2016; Storm, 1982]. The irregular and variable anatomy
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of GBM disease also mandates unique IMT hardware design. Rather than a single, in-line
row of contacts typical of DBS systems, comprehensive tumor coverage requires
bioelectrodes with versatile, multi-dimensional configurations driven by a field generator
capable of producing a unique spectrum of IMT parameters. DBS has traditionally used a
voltage-driven treatment platform, however newer devices are available that utilize
constant current parameters with or without directional control [Contarino, 2014;
Tagliati, 2015]. Tight regulation of current flow within disease-affected brain regions
may provide greater therapeutic impact when the goal is to re-program pathological firing
patterns in non-oncological disease; however, it remains unknown whether the same logic
applies to electrotherapies designed for CNS cancer. Conductive (uninsulated)
bioelectrodes may be powered by a voltage-driven system with the resultant current flow
gated by local tissue resistivity. The heterogeneous architecture of the brain and GBM
tumors would result in constant voltage with variable and dynamic current flow. In
contrast, the same bioelectrodes powered by a constant current platform could provide a
defined rate of flow maintained by feedback modulation that adjusts the voltage to
accommodate varying resistivity. A third option for IMT delivery is to establish an
intratumoral electric field without current flowing between the bioelectrodes and the
tissues using non-conductive (insulated) bioelectrodes within the GBM-affected region.
In the present work, IMT was voltage-driven with a peak-to-peak pulse amplitude of 4
volts (±2 V) which did not elicit overt behavioral changes, seizures, or focal neurological
deficits, nor histological evidence of electrolysis in the brain or tumor. As a pilot
investigation, a small fraction (2/15) of the cohort received insulated bioelectrodes with
other IMT parameters remaining constant. There was a positive treatment response in
these animals measured by both whole and core tumor analysis, indicating that an applied
intratumoral electric field may be sufficient to attenuate tumor growth. Further studies are
needed to define the properties of conductive versus non-conductive implanted
bioelectrodes in GBM disease.
This study demonstrated the in vitro efficacy of intermediate frequency IMT in patient
GBM cells and showed that a rudimentary, pilot IMT device could significantly reduce
GBM volume across a 15-animal cohort. This is the first demonstration that GBM tumors
may be therapeutically impacted using an implantable system to chronically deliver low

48

intensity, non-ablative electric fields. The current data provide strong justification to
develop IMT hardware and application settings that provide more comprehensive tumor
coverage and, hopefully, enhanced therapeutic benefit. Successful advances in IMT
technology could lead to a novel treatment modality desperately needed for GBM and
other high fatality CNS cancers.
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Chapter 3

3

Diffuse Intrinsic Pontine Glioma Cells are Vulnerable to
Low Intensity Electric Fields Delivered by Intratumoral
Modulation Therapy2

Introduction Diffuse intrinsic pontine glioma (DIPG) is a high fatality pediatric brain
cancer without effective treatment. The field of electrotherapeutics offers new potential
for other forms of glioma but the efficacy of this strategy has not been reported for DIPG.
This pilot study evaluated the susceptibility of patient-derived DIPG cells to low intensity
electric fields delivered using a developing technology called intratumoral modulation
therapy (IMT). Methods DIPG cells from autopsy specimens were treated with a customdesigned, in vitro IMT system. Computer-generated electric field simulation was
performed to quantify IMT amplitude and distribution using continuous, low intensity,
intermediate frequency stimulation parameters. Treatment groups included sham, IMT,
temozolomide (TMZ) chemotherapy and radiation therapy (RT). The impact of single
and multi-modality therapy was compared using spectrophotometric and flow cytometry
viability analyses. Results DIPG cells exhibited robust, consistent susceptibility to IMT
fields that significantly reduced cell viability compared to untreated control levels. The
ratio of viable:non-viable DIPG cells transformed from ~ 6:1 in sham-treated to ~ 1.5:1 in
IMT-treated conditions. The impact of IMT was similar to that of dual modality TMZ–
RT therapy and the addition of IMT to this treatment combination dramatically reduced
DIPG cell viability to ~ 20% of control values.

_________________
2

A version of this chapter is published as:

Andrew Deweyert, Erin Iredale, Hu Xu, Eugene Wong, Susanne Schmid, Matthew. O.
Hebb. (2019). Diffuse intrinsic pontine glioma cells are vulnerable to low intensity
electric fields delivered by Intratumoral Modulation Therapy. Journal of NeuroOncology. 43(1):49-56.
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Conclusions This proof-of-concept study provides a novel demonstration of marked
DIPG cell susceptibility to low intensity electric fields delivered using IMT. The potent
impact as a monotherapy and when integrated into multi-modality treatment platforms
justifies further investigations into the potential of IMT as a critically needed biomedical
innovation for DIPG.

3.1 Introduction
Diffuse intrinsic pontine glioma (DIPG), also called H3 K27M-mutant diffuse midline
glioma, is the most common brainstem cancer in children, representing 80% of tumors in
this region of the central nervous system (CNS) [Wu , 2012; Johung , 2017]. The average
age at diagnosis is 6–9 years old and affected children typically present with a
progressive spectrum of neurological deficits. Magnetic resonance imaging most often
reveals an expansile, T2-hyperintense, poorly-enhancing mass centered in the pons
[Harward, 2018]. The infiltration of DIPG within the brainstem parenchyma precludes
safe surgical resection. The mainstay of treatment is fractionated radiation therapy (RT)
which can provide transient symptom and tumor control resulting in median patient
survival of 9 months and a 2-year survival rate < 10% [Cohen, 2017]. Multiple
chemotherapy protocols and agents have been trialed but have not demonstrated further
survival benefit [Long, 2017; Gwak, 2017]. Despite international efforts in defining the
molecular underpinnings of DIPG, there have been no recent therapeutic advances that
substantially improve patient outcomes [Johung, 2017; Cohen, 2017].
There is emerging evidence that electrotherapy may offer a novel means to control
malignant glioma and considerable progress has been made treating the high fatality CNS
cancer, glioblastoma (GBM). A single clinical electrotherapy system with demonstrated
survival benefit has been approved for new and recurrent GBM. Unfortunately this
device is not engineered for the treatment of infratentorial tumors such as DIPG [Stupp ,
2012; Fonkem , 2012; Stupp , 2017]. Current PubMed searches using the terms diffuse
intrinsic pontine glioma and electrotherapy or electric fields produced no reports. Thus,
the potential impact of electrotherapy on DIPG remains unknown. Intratumoral
modulation therapy (IMT) is a developing technology which may offer an
electrotherapeutic option for tumors located anywhere within the CNS, including the
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brainstem [Xu, 2016; DiSebastiano, 2018]. IMT exploits the electrosensitivity of cancer
cells using implanted field-generating sources (e.g., bioelectrodes) to deliver nonablative, low intensity electric fields that attenuate tumor growth and bolster multimodality treatment platforms. Preclinical studies demonstrated potent efficacy of IMT as
a monotherapy and when combined with chemotherapeutic or oncogene-silencing agents
in primary human GBM cells and in vivo allogeneic GBM models [Xu, 2016;
DiSebastiano, 2018]. To date, however, there have been no reports of the application of
IMT to other CNS cancers. The goal of this pilot study was to determine the vulnerability
of patient-derived DIPG cells to low intensity electric fields delivered using an
established IMT protocol. The impact of IMT on DIPG resistance to conventional
radiation and chemotherapy options was also investigated.

3.2 Materials and Methods
3.2.1

Patient‐derived DIPG cells

Patient-derived DIPG cells, labeled SU-DIPG-IV, SU- DIPG-XIX and SU-DIPG-XXIV,
were kindly received from Dr. Michelle Monje at Stanford University. The tumor
collection protocol, culture methods at derivation, patient demographics and tumor
genetics have been previously described [Lin, 2017; Venkatesh, 2017; Qin, 2017;
Ostermann, 2004]. The cells were derived from early post- mortem DIPG specimens in
three pediatric patients, aged 2, 2, and 6 years old respectively, who had received
radiation and chemotherapy during their care. Upon arrival to the Hebb lab, frozen DIPG
cells were thawed and cultured in 6-well plates (Corning, NY, United States) at 37 °C
with humidified air containing 5% CO2 using NeuroCultTM NS-A medium
supplemented with 10% proliferation supplement, bFGF (10 ng/mL), EGF (20 ng/mL),
heparin sulfate (2μg/ ml) and 1% penicillin/streptomycin (Complete NSA; Stemcell
Technologies, Vancouver, B.C., Canada). The medium was changed every 72 h and
cultures passaged 1:2 at 70–90% confluence.
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3.2.2

In vitro IMT model

The impact of IMT alone and combined with temozolomide (TMZ) chemotherapy and/or
RT was evaluated using primary human DIPG cells cultured in 35 mm wells. The IMT
model was created by fitting each well with a clinical grade, platinum-based strip
bioelectrode (Ad-Tech Medical Instrument Corporation, Oak Creek, WI, USA) around
the periphery and platinum-iridium bioelectrode (Medtronic Ltd., Hertfordshire, United
Kingdom) at the center of the well and cell culture [Xu, 2016; DiSebastiano, 2018]. A
waveform generator (Rigol DG1022; Electro-Meters Ltd., Pickering, ON, Canada) was
used to deliver biphasic sinusoidal pulses with low amplitude (± 2 V; peak-to-peak 4 V)
and intermediate frequency (200 kHz) continuously over 3 days. Control wells (i.e. shamtreated) were fitted with bioelectrodes but did not receive stimulation.

3.2.3

IMT field simulation

The IMT electric field was simulated with COMSOL Multiphysics v 5.2a (Comsol Inc.,
Burlington, MA, USA) AC/DC module, electric currents user interface in the frequency
domain. The geometries of the in vitro model were manually created utilizing COMSOL
Geometry to generate an identical in silico model. The dish and electrode apparatus were
mimicked in geometry and the appropriate materials simulated utilizing known material
conductance and dielectric properties. The boundary conditions were applied as the edge
of the 35 mm dish. The centre stimulating electrode was set to emit a 2 V amplitude
waveform, and the outer electrodes were grounds. Electrical insulation on outer
boundaries was assumed. A mesh of the geometry was created, and a frequency of 200
kHz chosen for evaluation. The dimensions and amplitude of the electric field within the
culture dish were analyzed using MATLAB R2015b (MathWorks Inc., Natick, MA,
United States).

3.2.4

Multi‐modality treatment of DIPG cells

DIPG cells (1 × 105) treated with 50 μm TMZ were cultured in 35 mm wells fitted with
IMT bioelectrodes without stimulation (i.e., sham IMT) for TMZ monotherapy or while
receiving concurrent IMT during dual therapy. This TMZ concentration corresponds to
plasma levels obtained with 150 mg/m2 in the adjuvant treatment phase of other forms of
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glioma [15]. Additional DIPG samples received 4 Gy of ionizing radiation in a single
fraction using a Cobalt-60 irradiator with average dose rate of 74 cGy/min. This dose was
chosen after a RT dose–response study to permit evaluation of cooperative benefits
between different therapeutic modalities in vitro [Buch, 2012; Smyth, 2018]. The cells
were allowed to recover for 1 h after RT and were then plated into 35 mm wells fitted
with the IMT system. At this point, DIPG cells were cultured with no further treatment
(i.e., RT monotherapy group), or in the presence of TMZ (50 μM) or IMT (i.e., TMZ-RT
or IMT-RT dual therapy groups), or both TMZ and IMT (i.e., TMZ-RT- IMT multimodality therapy group) for 3 days.

3.2.5
Cell

Cell viability assay
viability

was

evaluated

using

the

3-(4,5-dimethylthiazol-2-yl)-2,5-

diphenyltetrazolium (MTT) spectral analysis (Sigma Aldrich, St. Louis, MO, United
States). This colorimetric assay measures the reduction of yellow MTT by mitochondrial
succinate dehydrogenase to an insoluble, dark purple formazan product. Immediately
following the DIPG cell treatments described above, MTT (80 μl at 5 mg/ml) was added
to the 35 mm wells and incubated for 3 h at 37 °C in a humidified 5% CO2 atmosphere.
The cells were then lysed to release the purple formazan product by the addition of 300 μl
dimethyl sulfoxide for 15 min at room temperature. Absorbance was measured using an
Epoch microplate spectrophotometer (BioTek, Winooski, VT, United States). Cell
viability was estimated using optical density values at 570 nm with references at 655 nm
detected in each well. Brightfield images of cells stained with MTT were obtained using
a Motic AE31 inverted microscope fitted with an Infinity 1–3 scientific complementary
metal-oxide semiconductor camera (Lumenera Corp, Nepean, ON, Canada).

3.2.6

Flow cytometry

Annexin V apoptosis detection with zombie red (ZR) was used to quantify fractions of
live, apoptotic and dead DIPG cells, as per the manufacturer’s instructions (BioLegend,
San Diego, CA, USA). Cell fractions were analyzed using a Becton Dickinson LSR II
SORP flow cytometer running FACSDiva software (BD Biosciences, Mississauga, ON,
Canada). Cells were first gated on forward scatter (FSC-) versus side scatter (SSC-)
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characteristics before excluding doublets using consecutive gating FSC-Area versus FSCWidth and SSC-Area versus SSC-Width plots. The populations of annexin V+/ZR−,
annexin V+/ZR+, annexin V−/ZR+ and annexin V−/ZR− were then calculated with
quadrant gates. Approximately 25,000 single cells were acquired per sample at a
maximum event rate of 5000 events per second. Data were analyzed using FlowJo v 9.6.3
software (TreeStar Inc., Ashland, OR, USA).

3.2.7

Statistical analysis

A t test was used to compare paired data sets. Multiple pairwise comparisons were
performed using one-way analysis of variance (ANOVA) followed by Tukey post hoc
analysis (SPSS Inc., Chicago, IL, USA). Data are presented as mean ± standard deviation
with significance assumed at p < 0.05.

3.3 Results
3.3.1

IMT field mapping for in vitro DIPG cell treatment

The in vitro IMT model utilized clinical grade, biocompatible, platinum (peripheral
ground) and platinum-iridium (central stimulating) bioelectrodes fitted within 35 mm
culture preparations of patient DIPG cells (Fig. 3.1a). A sinusoidal, biphasic waveform
with peak-to-peak amplitude of 4 V was chosen to create reversing polarity and
maximally disrupt the electrical environment using low intensity parameters known to be
innocuous within the living brain (Fig. 3.1b) [DiSebastiano, 2018]. The 200 kHz
stimulation frequency is below that needed to produce thermal injury and surpassed the
neuronal entrainment threshold to reduce the potential of off-target IMT effects when
translated to eloquent brain regions [Kirson, 2004; Palti, 1996; Storm, 1982]. The
bioelectrode configuration and stimulation parameters created a symmetric, low intensity
IMT field pattern across the DIPG cultures. The electric field was calculated by
simulating the in vitro experiments in COMSOL Multiphysics (v 5.3a) using the
electrode geometry presented and a constant voltage amplitude waveform generation.
Based on this simulation, the largest electric field coverage extended concentrically from
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the central stimulating bioelectrode with smaller fields generated at regular intervals
around the encircling peripheral bioelectrodes (Fig. 3.1c). The percent area coverage
across the culture dish was calculated and plotted over one cycle of the waveform for
electric field magnitude with thresholds in the range previously shown to be effective in
other glioma cancers (Fig. 3.1d) [Xu, 2016; DiSebastiano, 2018; Wenger, 2015; Wenger,
2016]. The coverage at the peak of the IMT waveform for each of the electric field
magnitude thresholds of 1, 0.75, 0.5 and 0.25 V/cm was 6.2%, 8.9%, 16.4% and 54.7%
respectively. Although other forms of glioma have been shown to require electric field
amplitude > 1 V/cm for optimal electrotherapy benefits, the threshold for DIPG response
is not known [Wenger, 2015; Wenger, 2016]. The therapeutic effects described below
were therefore generated with this pilot IMT model providing electric field coverage >
0.25 V/cm to roughly half, and 1 V/cm to only a small fraction of the DIPG culture area.

Figure 3-1. Computer simulation of the IMT model.
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a The IMT model was created using a central stimulating bioelectrode placed in a 3.5 cm
well along with eight peripheral grounded bioelectrodes. b A waveform generator
supplied a 200 kHz sinusoidal voltage with constant amplitude of 2 V to the central
electrode. c Applying such parameters to this configuration of bioelectrodes resulted in
an alternating electric field with the predicted magnitude and distribution plotted as
shown. d The percent area coverage across the culture dish reaching the electric field
thresholds in the range anticipated to exert biological impact are plotted as a function of
time over one cycle of the waveform. This pilot IMT system provided only fractional
field coverage to the DIPG cultures.

3.3.2

Patient DIPG cells are vulnerable to low intensity IMT
fields

Paired sham and IMT conditions were used to independently assess the impact of IMT
monotherapy on primary DIPG cells (SU-DIPG-IV, SU-DIPG-XIX, SU-DIPG-XXIV)
obtained from three pediatric patients. The 3-day exposure to low intensity IMT produced
a dramatic and consistent reduction in tumor cell viability. IMT-treated cultures were
sparse, pyknotic and exhibited faint MTT (formazan) labeling compared to sham-treated
DIPG cultures (Fig. 3.2a, b). Statistical assessment performed on MTT measures
normalized to those obtained in DIPG cells not exposed to IMT hardware (i.e., untreated
controls) revealed a significant reduction in viability following IMT (51.6 ± 16.0%) compared to sham (84.0 ± 33.0%) treatment (p = 0.046; Fig. 3.2c). Flow cytometry was
performed to confirm the MTT findings and evaluate the potential of apoptosis as a
mechanism of IMT effect on DIPG cells. The ratio of viable:non-viable DIPG cells
decreased from ~ 6:1 in sham-treated to ~ 1.5:1 in IMT-treated conditions (Fig. 3.3). The
significant reduction in DIPG cell viability was accompanied by a concordant rise in
apoptotic and dead cell fractions across all patient samples (Table 1).
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Figure 3-2. DIPG cells are highly susceptible to low intensity IMT.
Representative brightfield microscopy showing patient DIPG cultures following a 3-day
exposure to a sham or b IMT conditions. The cultures were stained with the viability dye,
MTT which produces a dark chromogen in viable cells. IMT-treated DIPG cells exhibited
marked pyknosis with reduced MTT labeling and density. c MTT measures in sham and
IMT treated cultures were normalized to those obtained in parallel cultures of untreated
DIPG cells. The IMT exposure produced a marked and significant reduction in DIPG
cells (asterisk; p = 0.046; n = 3; mean ± standard deviation). Scale bar represents 500 μm
for a and b.

Figure 3-3. IMT enhances apoptosis and death fractions in DIPG cell cultures.
a Representative flow cytometry scatterplots of annexin and the viability dye zombie red
(ZR) labeling of apoptotic and dead DIPG cells, respectively, after a 3-day exposure to a
sham or b IMT conditions. c Quantification of live and combined apoptotic/dead DIPG
cell fractions. In the sham-treated cultures, there was a marked, significant discrepancy
between these fractions that was attenuated in IMT treated cultures owing to the
significant rise in cell death. Asterisks immediately above the histogram bars indicate
significance between the live and apoptotic/dead fractions within the same treatment
group. Significance between indicated data pairs is depicted by the asterisk above the
horizontal bars. Data are presented as mean±standard deviation with significance
indicated at P: * < 0.05 and *** < 0.001.
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Table 3-1. Summary of flow cytometry data in patient DIPG cell samples

3.3.3

IMT significantly enhances multi‐modality treatment
platforms for DIPG

The impact of IMT monotherapy was compared to single agent TMZ chemotherapy and
RT, as well as combined approaches using dual or triple modality platforms (Fig. 3.4).
DIPG cells were treated with TMZ at a concentration equivalent to that achieved in
plasma during standard care for GBM, another form of high-grade glioma, with known
modest, yet significant therapeutic efficacy and an acceptable toxicity profile
[Ostermann, 2004]. The applied RT dose (4 Gy) in this study is known to have minimal
impact in DIPG cells when used as a monotherapy, based on in-house experience
(unpublished) and previous reports by other groups [Buch, 2012; Smyth, 2018]. This
dose was chosen to determine if the negligible efficacy could be bolstered by the addition
of TMZ and/or IMT to lessen the potential for adverse radiation effects when delivered in
vivo. MTT analysis was used to assess the viability of DIPG cells following parallel 3day exposures to sham IMT (i.e., hardware placement without stimulation) or IMT with
or without TMZ, RT or combined TMZ-RT. All MTT measures were normalized to those
of untreated DIPG controls. The sham IMT conditions had little effect on DIPG cells and
yielded 96.0 ± 6.6% viability. Monotherapy TMZ and RT was assessed in culture wells
fitted with a sham IMT system. TMZ (81.1 ± 17% viability; p = 0.564) and RT (72.2 ±
11.9% viability; p = 0.105) produced slight reduction in MTT values that were not
statistically different from the sham-only controls. In contrast, the combined TMZ-RT
exposure (which also included the sham IMT hardware) produced a mean DIPG cell
viability of 58.9 ± 11.3% which was significantly reduced relative to the sham-only
treated cells (p = 0.004).

63

Figure 3-4. IMT significantly augments multi-modality treatment platforms for
DIPG.
TMZ, low dose RT and IMT were applied to patient DIPG cultures in 3-day mono- and
multi-modality therapies. The MTT viability assay was used to evaluate the impact of
each treatment and the resultant data normalized to the mean MTT value obtained in
untreated control DIPG cells. Monotherapy TMZ and RT were delivered in culture wells
fitted with sham IMT hardware and neither had a significant impact on DIPG cells. In
contrast, dual TMZ-RT exposure dramatically reduced DIPG cell viability. The IMT
effect did not differ significantly from that of dual TMZ-RT therapy. However, the
addition of IMT to the TMZ-RT combination produced marked and highly significant
added therapeutic impact and a resultant DIPG viability of approximately 20% of
untreated controls. Asterisks immediately above the histogram bars indicate significance
between that specific treatment group and sham control. Significance between indicated
data pairs is depicted by the asterisk(s) above the horizontal bars. Data are presented as
mean±standard deviation with significance indicated at P: * <0.05, ** <0.01 and *** <
0.001
IMT monotherapy resulted in DIPG cell viability of 44.2 ± 7.7% which was also
significantly reduced compared to sham values (p < 0.001) and significantly more
effective than either TMZ (p = 0.005) or RT (p = 0.045) conditions. Dual therapy created
by the addition of IMT significantly reduced DIPG cell viability compared to
monotherapy TMZ (81.1 ± 17% vs. 40.1 ± 2.50%; p = 0.002) or RT (72.2 ± 11.9% vs.
34.7 ± 4.4; p = 0.004). In contrast to TMZ and RT monotherapies, the MTT-measured
impact of IMT alone was not significantly different than the combined TMZ-RT
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treatment (p = 0.614). Likewise, the therapeutic effect of combined TMZ-RT exposure
was not significantly different from dual modality exposure to IMT-TMZ (p = 0.315) or
IMT-RT (p = 0.113). Most notably, however, the impact of dual therapy TMZ-RT was
potently enhanced by the addition of IMT in the multi-modality treatment plat- form
TMZ-RT-IMT (58.9 ± 11.3% vs. 20.50 ± 7.8% viability, respectively; p = 0.004).

3.4 Discussion
This study provided novel evidence of DIPG cell vulnerability to low intensity electric
fields delivered using an established preclinical IMT protocol. IMT produced apoptotic
tumor cell death using stimulation parameters previously demonstrated to be noninjurious to normal neural cells in vitro and in vivo [Xu, 2016, DiSebastiano, 2018]. The
applied stimulation frequency of 200 kHz is above the range for neural entrainment and
below that for thermal injury [Palti, 1996; Storm, 1982]. IMT monotherapy reduced
DIPG cell viability by ~ 50% and was more efficacious than either low dose RT or a
clinically utilized concentration of TMZ. The addition of IMT to the combined TMZ-RT
paradigm dramatically reduced DIPG cell viability from ~ 60% to 20%. It remains
unclear how IMT incites glioma cell death. There is evidence that non-ablative, nonthermal, low intensity electric fields work through multiple anti-neoplastic mechanisms
that disrupt polarized molecules necessary for cell division, membrane permeability and
channel homeostasis [Pawłowski, 1993; Gera, 2015]. In GBM studies, IMT has been
shown to enhance the impact of TMZ and oncogene-targeted therapy as well as the
uptake of hydrophilic genetic inhibitors [Xu, 2016]. The apparent lack of effect on postmitotic neurons or in normal brain parenchyma suggests that IMT exploits
electrochemical vulnerabilities related to the neoplastic phenotype. Further studies are
required to better understand these issues.
One possible method of providing IMT to DIPG entails custom configured, implanted
bioelectrodes to perpetually deliver therapeutic electric fields across tumor-affected CNS
regions using a concealed, titratable system that works cooperatively within a multimodality treatment platform. Radiation is currently first line care for DIPG and, in this
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study, produced cooperative anti-neoplastic impact when delivered concurrently with
IMT [Cohen, 2017]. While chemotherapy has not shown significant benefit in DIPG for a
potential host of reasons, TMZ is commonly used and beneficial in other forms of
malignant glioma [Gwak, 2017; Ostermann, 2004]. In this study, the insignificant impact
of RT or TMZ monotherapies was in contradistinction to the potent effect of the triple
IMT/RT/TMZ combination, suggestive of sensitizing interactions that dramatically
improve overall treatment efficacy. It remains to be determined if this efficacy will
persist in vivo, and whether the multi-modality platform brings any unexpected toxicities.
With respect to safety, a key putative advantage of the envisioned clinical IMT system is
the ability to titrate, re-configure and discontinue stimulation. Reversibility of effect with
therapy cessation, as typical with conventional forms of neuromodulation such as deep
brain stimulation (DBS), is likely given the low amplitude and apparently benign nature
of applied IMT fields in normal brain [DiSebastiano, 2018; Udupa, 2015; Wichmann,
2016; Herrington, 2016].
The most readily available IMT prototype will likely include multi-contact leads
stereotactically positioned within the brainstem and powered by an indwelling pulse
generator. Surgical access to the brainstem is routinely achieved for various neoplastic
and non-neoplastic indications and does not present an obvious barrier to development
and safe application of IMT for DIPG patients. For example, there has been recent
progress directly targeting DIPG tumors with catheters used for convection-enhanced
delivery (CED) of pharmacotherapies [Morgenstern, 2018; van Vuurden, 2018]. While
the outcome of the neoplastic disease was not altered using CED, there were no
significant adversities that resulted from implanting catheters within the DIPG tumors. A
longstanding, global experience with DBS provides another important example of the
feasibility to implant hardware in the brainstem for treating neurological disease. DBS is
the standard of surgical care for Parkinson’s Disease (PD) where electrodes are
chronically implanted into the subthalamic nucleus and often extending into the
mesencephalic

substantia

nigra

[Habets,

2018;

Ramirez-Zamora,

2018].

The

pedunculopontine nucleus is another brainstem target being evaluated for implanted
neuromodulation systems to improve postural and gait instability in PD [Nowacki, 2018].
It is important to note that DBS and IMT are starkly different in neurological indication,
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operational parameters and hardware design. The electrical output of putative IMT
systems will be defined by customized waveform, polarity, and stimulation parameters
titrated to individual tumor response and regional anatomy. DBS technology typically
delivers continuous, monophasic, square wave pulses at low frequency (e.g., 90–185 Hz)
to disrupt and entrain pathological firing patterns [Udupa , 2015; Wichmann , 2016;
Herrington, 2016]. In contrast, the present IMT system used an intermediate frequency
(200 kHz), sinusoidal waveform with reversing polarity intended to maximally disrupt
electrical homeostasis in DIPG cells. The pulse frequency was 1000-fold higher than
typical DBS settings and well out of range for neuronal entrainment in order to
selectively target neoplastic cells while averting adverse neurological effects when
stimulating tumor-infiltrated CNS regions [DiSebastiano, 2018; Palti, 1996; Hottinger,
2016]. Additionally, the hardware configuration required to deliver personalized,
comprehensive IMT field coverage will likely be sharply divergent from that of
contemporary DBS electrodes designed to provide highly discrete zones of stimulation.
This proof-of-concept study provided novel evidence of DIPG cell susceptibility to low
intensity electric fields delivered using an IMT strategy. The significant treatment
response was produced in a pilot IMT model with incomplete field coverage, suggesting
even greater efficacy may be realized using a comprehensive delivery system.
Additionally, these DIPG cells were derived from fresh autopsy tissue that had been
previously exposed to chemotherapy and RT, possibly selecting for tumor cells with
heightened treatment resistance. The impact of IMT-based platforms measured in this
study may therefore underestimate that attainable in treatment-naïve DIPG cells. While
the present observations have yet to be replicated in larger, genetically-diverse cohorts
and translational models, these exciting early data provide a new glimpse at the potential
of electrotherapeutics to improve the otherwise devastating outcome for DIPG patients.
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Chapter 4

4

Simulation and treatment of high-grade glioma with
dynamically-oriented electric fields3

Introduction: Intratumoral modulation therapy (IMT) is an emerging strategy to control
high grade glioma (HGG) with low intensity electric fields delivered by implantable
electrodes. The treatment parameters that provide maximal tumor coverage are unknown
and direct evidence of IMT efficacy in solid human HGG tumors is lacking. This study
quantified the impact of electrode and waveform variations on electric field properties
and IMT response in novel human spheroid and organoid HGG models.
Methods: Computer simulations were used to determine the IMT field generated from a
multi-electrode configuration based on the applied waveforms and the relative phaseshifts from each electrode. Optimized IMT parameters were then evaluated for
therapeutic efficacy in patient-derived, engineered spheroid and naive organoid HGG
models, and for adverse neurological and histological impact in living rodent brains.
Results: Simulation analysis demonstrated robust advantage in achieving planned electric
field amplitudes and distributions using multiple compared to single electrode IMT
systems. The transition to a phase-shifted output waveform to create dynamicallyoriented electric fields further dramatically improved tumor coverage. Optimized, phaseshifted IMT parameters produced significant reduction of tumor cell viability in patientderived HGG spheroids and solid organoids without overt neurological effects or tissue
electrolysis in normal living rodent brain.
__________________
3

A version of this chapter is going to be published as:

Andrew Deweyert, Erin Iredale, Hu Xu, Eugene Wong, Susanne Schmid, Matthew. O.
Hebb. (2021). Malignant glioma sensitivity to dynamically-orientated electric fields
delivered by intratumoral modulation therapy. In preparation for submission.
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Conclusions: Phase-shift IMT strategies using multiple electrodes produce dynamic,
impactful electric fields for comprehensive tumor coverage in human glioma models.
This work presents the first direct evidence of IMT response in solid patient HGG
specimens.

4.1 Introduction
Glioblastoma (GBM) is the most common high-grade glioma (HGG) and brain cancer
arising from the adult central nervous system (CNS) [Nam, 2017]. Maximal safe
resection followed by chemo- and radio-therapy is standard treatment yet fails to achieve
long-term disease control in most patients. The field of electrotherapeutics holds promise
in cancer care, including for GBM and other HGGs, but remains largely under-developed
[Mun, 2018]. Tumor cells from a host of somatic and nervous system cancers are
sensitive to exogenous, low intensity electric fields [Xu, 2016; Krison, 2004]. Glioma
cells, including those derived from GBM, are among those vulnerable to non-ablative
stimulation that exerts negligible physical impact on normal brain tissues [DiSebastiano,
2018]. Multiple biological effects in neoplastic cells have been reported including mitotic
spindle disruption, direct DNA damage, autophagic responses and increased membrane
permeability [Ghiaseddin, 2009; Chang, 2018; Karanam, 2020; Robins, 2018]. The key
anti-tumor benefits of low intensity electric fields appear to be the induction of targeted
apoptosis and enhanced efficacy of combination treatment platforms [Xu, 20016;
DiSebastiano, 2018; Deweyert, 2019].
The emerging concept of intratumoral modulation therapy (IMT) employs an implanted
array of electrodes to deliver personalized, low intensity electric fields across tumoraffected CNS regions. The intent of this strategy is to create a means of chronic tumor
suppression administered alongside, and beyond, standard treatment options. IMT fields
could span contrast-enhancing and non-enhancing diffuse or focal tumors, and target
unresected glioma or tumor resection beds anywhere in the CNS. Early studies
demonstrated robust in vitro efficacy of IMT monotherapy in glioma cells, but not
primary neurons, and markedly enhanced impact of chemotherapy and radiation with
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adjuvant IMT [Xu, 2016; Deweyert, 2019]. The in vitro treatment parameters were
translated to an in vivo rodent GBM model using a rudimentary IMT system that
produced significant reduction in tumor volume but no neurological deficits or tissue
injury when delivered to normal brain [DiSebastiano, 2018]. These pilot data raised
enthusiasm for further evaluation of IMT in glioma tumors but also highlighted important
shortcomings of the early system design. For example, the in vivo studies used a single
stimulating electrode positioned within the tumor, coupled to an extracerebral ground
electrode. GBM viability was reduced even though post-hoc simulation analysis revealed
tightly confined electric fields that spanned only a fraction of the tumor region
[DiSebastiano, 2018; Deweyert, 2019]. The elicited responses were significant but
undoubtedly did not reflect the full capacity of IMT in these models. The field coverage
may be improved by modifying individual programming specifications, such as output
waveform, amplitude, frequency, electrode number and position, amongst others. In
particular, IMT configurations using multiple electrodes will accommodate a wide
spectrum of stimulation parameters, including phase-shifted output waveforms to produce
rotatory, migrational, or multi-directional (i.e., dynamically-oriented) fields with better
tumor coverage than those generated by comparable in-phase waveforms [Iredale, 2020].
The present study seeks to validate these principles of enhanced IMT in preclinical
human HGG applications. Specifically, this work compares simulated electric field
distribution and target amplitudes achieved using single versus multiple stimulating
electrodes and bi-directional versus dynamically-oriented electric fields. The optimized
parameters defined by the simulation analysis are then applied in a sentinel evaluation of
IMT in novel 3-dimensional (3D) human tumor models using patient-derived HGG
spheroids and naïve solid organoids.

4.2 Materials and Methods
4.2.1

Glioma spheroid and organoid preparations

This study was approved by the Human Research Ethics Board at Western University and
carried out in accordance with the Tri-Council Policy for research involving human
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subjects. Informed consent for tumor and control tissue was obtained from all patients or
their legal guardians and tumor diagnosis was confirmed by a neuropathologist.
Clinically relevant genetic profiling was performed at the neuropathologist’s discretion
but not used as study inclusion/exclusion criteria. Tumor specimens were initially
collected into DMEM in the operating room and transferred promptly to the lab for cell
culture or organoid preparation [Xu, 2016; DiSebastiano, 2018]. Glioma cells from 5
patient tumors were transduced with a lentiviral vector encoding firefly luciferase (FLuc)
driven by the constituitive elongation factor 1 alpha promoter to create primary 3D
spheroids amenable to real time monitoring with bioluminescence imaging (BLI)
[Parkins, 2020; Hamilton, 2018]. HGG spheroids were created in 7 mm diameter culture
wells by implanting tumor cells (4x104 cells in 2 μL phosphate-buffered saline (PBS))
into 200 μL Matrigel matrix (Corning) over a 2-minute period. The matrix with
embedded tumor cells was allowed to polymerize at 37 °C with 5% CO2 for 20 minutes
before the addition of 100 μL of complete Dulbecco's modified Eagle's medium (DMEM;
Wisent Bioproducts) containing 10% fetal bovine serum (FBS; Life Technologies), 1%
non-essential amino acids and 1% penicillin/streptomycin (Life Technologies).
Solid glioma organoids and non-neoplastic brain organoids were prepared from an
additional 5 patient tumors and 6 non-neoplastic neurosurgery patients respectively. The
tissue was washed with PBS and 5 mm punch samples (Integra Milex) suspended in a 7
mm diameter culture well containing 100 μL Matrigel (Corning). The matrix with
embedded tumor fragment was allowed to polymerize at 37 °C with 5% CO2 for 20
minutes before the addition of 100 μL of NeuroCultTM NS-A medium supplemented
with 10% proliferation supplement, bFGF (10 ng/mL), EGF (20 ng/mL), heparin sulfate
(2μg/ml) and 1% penicillin/streptomycin (Stemcell Technologies).
Multi-electrode IMT model
A 3-electrode device was custom designed and fabricated for preclinical evaluation of
expanded IMT parameters, including phase-shifted waveforms, in 3D glioma models.
The hardware was adapted for 7 mm culture wells with embedded tumor spheroids and
organoids, as described above, and consisted of three biocompatible, uninsulated,
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platinum electrodes (6 mm length, 0.25 mm diameter, 2 mm inter-electrode distance)
mounted to a common pedestal made of polyether ether ketone. A thread and groove
system on the pedestal allowed fixation to a modified culture lid and secure cable
connection to the waveform generator (Rigol DG1022; Electro-Meters Ltd). The device
was positioned within the Matrigel 24 hours following spheroid or organoid implantation
to create sham control (i.e., implanted hardware but no stimulation) or IMT conditions for
a 72-hour period using electrode configurations guided by the simulation analysis. A
third tumor specimen provided a no-hardware control scenario for each run.

4.2.2

Computer simulation of IMT electric fields

The computer simulations used physical geometries of the culture models so that in silico
treatment parameters could be subsequently evaluated in HGG spheroids and organoids.
Simulated electric field maps generated using the following electrode configurations were
evaluated: 1) a single stimulating electrode with a paired ground electrode, 2) 2
stimulating electrodes using in-phase waveforms with 1 ground electrode and 3) 3
electrodes each with an equal 120 degree phase-shift between output waveforms [Iredale,
2020]. The electrical output of all configurations included a sinusoidal waveform of 4V
peak-to-peak amplitude (+/-2V, max/min) and 200 kHz frequency which have previously
been effective in HGG cell culture and in vivo models [DiSebastiano, 2018; Deweyert,
2019]. IMT models were constructed using the AC/DC module, electric currents user
interface in COMSOL Multiphysics (v 5.4) with biocompatible, platinum stimulating and
ground electrodes. The 3-electrode model permitted a choice of waveform for each
electrode, including selection of relative phase-shifts. Material electrical properties of
conductivity and relative permittivity were assigned to the components of the treatment
models, with respective values of 1.5 S/m and 81 for Matrigel and 9.43 x 106 S/m and 1
for the platinum electrodes [Taghian, 2015; Arnold, 1994; Chen, 2009]. Terminal
boundary conditions were applied to each electrode and electrical insulation was assumed
on all outer boundaries of the model [Iredale, 2020]. A tetrahedral mesh was used and the
electric field computed over a waveform period for each scenario. The average electric
field delivered to each voxel over time was analyzed in MATLAB R2020b using the
COMSOL MATLAB Livelink to generate average electric field maps and electric field
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volume histograms (EVH) outlining the percentage of Matrigel tumor bed volume
covered by the corresponding time average electric field.

4.2.3

Tumor viability assays

Spheroid viability was measured using BLI emission intensity captured with a cooled
CCD camera mounted in a light-tight specimen box (IVIS hybrid optical/Xray scanner,
IVIS Lumina XRMS, PerkinElmer) [Parkins, 2020]. The luciferase substrate, D-luciferin
(300 μg/mL), was added to the culture media following the treatment period and imaging
performed at 60 second intervals until peak signal was obtained and the mean photon flux
(photons/second/mm2) measured (Living Image, Xenogen). A second measure of
spheroid

viability

was

obtained

using

the

3-(4,5-dimethylthiazol-2-yl)-2,5-

diphenyltetrazolium (MTT) assay (Sigma Aldrich). This spectrophotometric test
measures the reduction of yellow MTT by mitochondrial succinate dehydrogenase to an
insoluble, dark purple Formosan product. Following treatment, MTT (20 μl at 5 mg/ml)
was added to the culture media and spheroids incubated for 3 hours at 37 °C in a
humidified 5% CO2 atmosphere. Spheroids were then lysed to release the purple
Formosan product by the addition of 80 µl dimethyl sulfoxide (DMSO) for 15 minutes at
room temperature. Absorbance was measured using a microplate spectrophotometer
(Epoch) and viability estimated using optical density values at 570 nm with references at
655 nm [Taghian, 2015; Chen, 1994].
Glioma and control organoids were similarly assessed using the MTT assay. However,
these solid tumor specimens did not readily lyse with DMSO for measuring absorbance
so viability was quantified using densitometry analysis (ImageJ, version:2.0.0-rc69/1.52p). Tissue density readings were obtained by isolating the organoid image using
the automated thresholding tool. The optical density was then measured using the
analysis tool to produce a densitometry plot. The area under the plot was quantified and
normalized to the cross-sectional area of the corresponding organoid to account for
variations in organoid size. All BLI, MTT and densitometry values obtained following
sham or IMT conditions in spheroid and organoid models were normalized to the
respective no hardware control measures.
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4.2.4

In vivo IMT control studies

The same 3-electrode device and phase-shift IMT parameters described above were
evaluated in normal rodent brain to assess for neurological and lesional adverse effects.
IMT devices were stereotactically implanted under isoflurane anesthesia bilaterally into
the striatum in 3 male Fischer rats (coordinates from bregma: anteroposterior 1 mm,
lateral +/−3 mm, dorsoventral −6 mm). On postoperative day 4, IMT was randomized to
the right or left side and the respective device connected to a waveform generator (Rigol
DG1022; Electro-Meters Ltd) via an extension cable and a commutator that permitted the
animal to move freely throughout the home cage [Di Sebastiano, 2018]. The contralateral
hemisphere served as an internal sham control (i.e., identical hardware implants but
without stimulation). Continuous multi-electrode, phase-shift IMT was delivered between
postoperative days 4–11 with the same parameters used to treat the HGG spheroids and
organoids. All animals were given free access to food and water, perioperative antibiotics
and analgesics, and monitored daily for medical or neurological complications. On
postoperative day 11, animals were deeply anesthetized with sodium pentobarbital and
transcardially perfused with 4% paraformaldehyde. Brains were cut on a cryotome into
25 µm thick sections through electrode implantation sites, mounted onto microscope
slides and stained with thionine. Processed sections were digitally imaged with a Nikon
Eclipse Ni-E microscope.

4.2.5

Statistical Analysis

Datasets were compared using a Student’s t-test with significance considered at p-values
< 0.05 (Graphpad Prism8, CA, USA). Values are presented as mean ± standard
deviation (SD).
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4.3 Results
4.3.1

Phase-shifting markedly enhances IMT electric field
distribution

The computer simulation modeled various electrode configurations and treatment
parameters that could be evaluated using the newly fabricated IMT device for patient
HGG spheroids and organoids (Fig. 4.1). Specifically, these studies compared the electric
field distribution and amplitude resulting from a single stimulating electrode versus a
multi-electrode strategy that more accurately reflects the clinical vision of IMT. The 3electrode construct used here provides the simplest form of multi-electrode IMT that can
accommodate a phase-shift approach and create a dynamically rotating electric field
about the central axis of the construct. The geometry of the hardware was replicated in
COMSOL with 2 or 3 biocompatible platinum stimulating or ground electrodes. The
electric field threshold of 1 V/cm is recognized as effective in GBM and was used as an
exemplary measure of IMT coverage for each electrode configuration [Latikka, 2019;
Palti, 1966; Ghiaseddin, 2020]. Based on the EVH analysis, this amplitude was achieved
across 99% of the target treatment volume (i.e., culture well) using the phase-shift, multielectrode configuration, compared to 55% and 63% coverage using 2-electrode and 3electrode stimulation without phase-shift, respectively. Similarly, the volume percentage
covered by 2 V/cm for the 2-electrode, 3-electrode without and with phase-shift was
23%, 30%, and 68% respectively. Of the 3 configurations, only the phase-shift, multielectrode stimulation produced symmetric, dynamically rotating electric fields (Fig. 4.1).
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Figure 4-1. Transition from single to multiple stimulating electrodes with phaseshift output enhances electric field coverage.
A) A 3D IMT model was created in which broad variations in stimulation parameters
could be evaluated in patient-derived HGG spheroids and GBM organoids. B) Photo
showing the modified culture plate that accommodates fixed implantation of the IMT
electrode device into the tumor bed and connection of the device to a waveform
generator. C) Custom fabricated preclinical IMT multi-electrode device used both in the
3D HGG models and in vivo control rat brains5. D)-F) Cross sectional area of the 3D
culture well is shown with computer simulation of the IMT model using COMSOL
geometry to produce time average electric field maps for D) 2 electrodes (1 stimulating +
1 ground), E) 3 electrodes (2 in-phase stimulating + 1 ground), and F) 3 stimulating
electrodes equally phase-shifted. The transition to a multi-electrode, phase-shifted output
created marked improvement in field distribution, with less cold spots due to field
cancellation effect (Also see Supplementary video Fig S1). G) Graphical depiction of the
waveform output for 1 stimulating + 1 ground or 2 in-phase stimulating + 1 ground
scenarios. The single or overlapping (in-phase) waveforms result in limited electric field
distribution. H) In contrast, the phase-shift IMT scenario, with a 120-degree offset
between waveforms, produces a broad, dynamically-oriented electric field. I) Electric
volume histograms of IMT field coverage with each of the stimulation scenarios. Only
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the phase-shift 3-electrode configuration reached a 1 V/cm threshold known to impact
HGG viability across nearly 100% of the culturing well [Iredale, 2020].

4.3.2

Patient demographics and HGG specimens

Ten patients provided HGG specimens for this study (3 male: 7 female, age 29-75 years).
All tumors were supratentorial in location. Of the 9 HGG tumors diagnosed as GBM, 8
were de novo and 1 transformed from an anaplastic astrocytoma which had been treated
with surgery and chemoradiation 2 years prior. The remaining tumor sample was
obtained from a stereotactic biopsy in the youngest patient, who had no tumor history,
and diagnosed as anaplastic astrocytoma (Table 4.1).
Table 4-1. Patient and tumor characteristics.

4.3.3

Evidence of HGG spheroid response to IMT

The HGG spheroid model enabled the first multi-modality assessment of IMT impact
within a 3D tumor environment. Spheroids were created in triplicate for parallel 3-day
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exposure to 1. no hardware control, 2. sham and 3. IMT conditions. Based on superior
field coverage revealed by the computer simulation data, the 3-electrode construct was
applied using phase-shifted sinusoidal output of 4V peak-to-peak at a frequency of 200
kHz. Five biological replicates were assessed using MTT and BLI with sham and IMT
values normalized to the corresponding no hardware control measures. The MTT assay
revealed marked viability loss following IMT compared to sham (52.2 ± 6.4% : 100.4 ±
6.5% of no hardware control values, respectively; n = 5; p < 0.001; Fig. 4.2). The BLI
intensity measured in an independent series revealed consistently dramatic loss of
viability following IMT compared to sham treatment (18.9 ± 16.6% : 105 ± 32% of
control values, respectively; n = 5; p > 0.001). No overtly recalcitrant tumors were
identified, including the anaplastic astrocytoma in patient 1 and recurrent GBM in patient
5 which were both exquisitely sensitive to IMT (Fig. 4.3).

Figure 4-2. Phase-shift IMT reduces patient HGG spheroid viability.
A, B) Representative photographs showing the MTT assay in 3D HGG spheroids
following 3-day exposure to sham or IMT conditions, as indicated. Note the dramatic
reduction of the dark Formosan MTT product, consistent with viability loss, following
IMT C) MTT measures were normalized to the respective no-hardware control values
and revealed ~50% reduction in HGG spheroid viability with IMT compared to sham (n
= 5, *p < 0.001). Individual values are shown together with the cohort mean (horizontal
line) ± SD.

82

Figure 4-3. BLI reveals the robust impact of IMT in patient-derived HGG
spheroids.
A) Peak BLI signal from patient-derived HGG spheroids following 3-day exposure to
sham or IMT conditions. There was a dramatic loss of signal intensity following dynamic
field IMT compared to sham treatment in all specimens. B) BLI measures were
normalized to the respective no-hardware control values and revealed >80% reduction in
HGG spheroid viability with IMT compared to sham (n = 5, *p > 0.001). Individual
values are shown together with the cohort mean (horizontal line) ± SD.

4.3.4

Solid GBM organoids are highly sensitive to phaseshift IMT that does not injure normal brain
parenchyma

A 3-day parallel period of no hardware control, sham or IMT conditions was
implemented with 5 biologically distinct HGG and control organoids, all organoids in
this series, followed by evaluation with MTT densitometry to estimate tissue viability.
Consistent with the spheroid data, naïve GBM organoids exhibited marked sensitivity to
multi-electrode, phase-shift IMT. The post-treatment MTT density was visibly reduced
following IMT. The impact did not appear ablative and margins of the tumor fragments
remained delineated. Organoid viability measures decreased to 58.1 +/- 14.7% compared
to 101.4 +/- 11.7% of control values following IMT or sham conditions, respectively (n =
5; p = 0.003; Fig. 4.4). In contrast to the impact on GBM organoids, IMT did not produce
overt alterations in morphology or viability of non-neoplastic brain organoids taken from
epilepsy and benign axial tumor patients (relative MTT values: sham = 96.92±6.10%;
IMT = 104.80±11.13%; p = 0.1605; Figure 4.5). A control cohort of Fischer rats (n=3)
was then used to determine if the new multi-electrode, phase-shift IMT parameters would
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produce overt functional deficits or parenchymal injury in normal (i.e., non-tumorbearing) living brain. During a 1-week trial of dynamic field IMT, the animals exhibited
no changes in feeding, grooming, sleeping, nor any overt seizures or motor weakness.
The postmortem histology revealed expected parenchymal disruption along the electrode
tracts with no signs of electrolysis or substantial hemorrhage in either sham or IMTtreated hemispheres (Fig. 4.6).

Figure 4-4. Patient GBM organoids are highly sensitive to dynamically-oriented
electric fields.
HGG organoids, all diagnosed as GBM, were created from patient tumor specimens
immediately following surgical resection. A) Representative photographs depicting 5
GBM organoid cultures exposed to MTT following sham or dynamic field IMT
conditions. B) Quantification of GBM organoid viability with densitometry analysis.
MTT measures were normalized to the respective no-hardware control values and
revealed >40% reduction in organoid viability with IMT compared to sham (n = 5, *p =
0.003). Individual values are shown together with the cohort mean (horizontal line) ± SD.

Figure 4-5. Multi-electrode phase-shift IMT does not produce overt injury nonneoplastic brain organoids.
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Normal brain organoids, were created from patient specimens immediately following
surgical resection from epilepsy patients. A) Representative photographs depicting 5
brain organoid cultures exposed to MTT following sham or dynamic field IMT
conditions. B) Quantification of brain organoid viability with densitometry analysis.
MTT measures were normalized to the respective no-hardware control values and
revealed a non-significant difference in brain organoid viability with IMT compared to
sham (n = 6, p= 0.1605). Individual values are shown together with the cohort mean
(horizontal line) ± SD.

Figure 4-6. Multi-electrode phase-shift IMT does not produce overt injury in the
normal living brain.
The multi-electrode devices used in the HGG spheroid and organoid models were
implanted bilaterally in the brain of living rats with one hemisphere randomized to 1
week of sham conditions (i.e., hardware but no stimulation) and the other to phase-shift
IMT [5,9]. Representative sections are shown from each brain, numbered 1-3, and stained
with thionine. Symmetric defects from the electrode passages were evident bilaterally
(arrows) without overt parenchymal injury related to the stimulation.

4.4 Discussion
This study provided the first simulation and validation platform for multi-electrode IMT
in 3D patient-derived HGG models. These efforts demonstrated the dramatic field
distribution advantage of multiple versus single electrodes, and of phase-shift versus inphase output waveforms. The computer simulation allowed comparison of treatment
strategies in these proof-of-concept preclinical models that sets groundwork for advances
in electrotherapy planning systems for CNS cancer. The demonstration that multiple
electrodes provide greater tumor coverage than a single electrode is perhaps intuitive;
however, the delivery of such complex electric fields requires careful programming to
avoid untoward cumulative or cancellation effects [Iredale, 2020]. These challenges may
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be mitigated by phase-shifting, or temporally offsetting, output waveforms to create
dynamically-oriented electric fields that produce broader coverage than with in-phase
delivery. The current stimulation parameters did not produce overt injury to human nonneoplastic organoids and normal living brain but yielded powerful control of HGG
spheroids and naive human GBM organoids, providing resounding evidence of
therapeutic potential.
The new concept of IMT is distinct from existing electrotherapeutics in the application of
an indwelling source of personalized electric fields to yield perpetual CNS cancer
control. The stimulation parameters ideally would not produce neural entrainment or
interference to permit overlap between tumor and normal tissue without inciting adverse
effects. The kHz waveform frequency applied here is above neural entrainment range
however its safety and efficacy have not been established by long-term clinical
experience using implantable CNS electrodes [Latikka, 2019; Palti, 1966; Ghiaseddin,
2020]. Deep brain stimulation (DBS) is a common neuromodulation technique to quell
the symptoms of various non-oncological conditions, such as Parkinson’s Disease (PD),
and presently the only clinical indication for chronic intracerebral electrodes [Kogan,
2019]. DBS is typically delivered at low voltage (< 5V) and frequency (90-180 Hz) to
create highly focused electric fields at precise anatomic targets. The low frequency
incites neural entrainment to subvert pathological firing patterns but adds risk of offtarget stimulation effects (e.g., paresthesia, motor contractions) [Jakobs, 2019]. A recent
DBS trial in PD patients evaluated an initial experience using kHz stimulation, intending
to maintain therapeutic efficacy with reduced side effects. The team reported similar
symptom control in patients receiving low (i.e., Hz) and kHz-range frequencies. The
novel kHz-DBS was associated with less adverse impact and no patient safety concerns
[Harmsen, 2019]. The question remains however whether these parameters could
interfere with normal neural activity through alternate mechanisms when the electric
fields are more broadly distributed across CNS regions, as intended with IMT-based
strategies. This concern requires further attention but may be eased by the clinical
experience with an approved externally-applied electrotherapeutic for GBM. Compared
to the indwelling IMT delivery system, the external device is mounted on the scalp to
create low amplitude, kHz-range transcranial electric fields without significant
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neurological adversity [Stupp, 2017]. These experiences safely treating PD and GBM
with kHz stimulation align with the absence of neurological deficits or tissue injury in the
present study using implanted electrodes to create 200 kHz dynamic electric fields in the
living rat brain.
The cumulative data support preclinical IMT efficacy in various HGGs (i.e., anaplastic
astrocytoma, de novo and recurrent GBM, diffuse intrinsic pontine glioma) grown in
monolayer and 3D cell culture, patient-derived organoids and in vivo allografts [Xu,
2016; DiSebastiano, 2018; Deweyert, 2019]. Emerging image- and simulation-guided
algorithms may help define electrode number and placement, as well as treatment
parameters that yield optimal coverage [Iredale, 2020]. The therapeutic promise of IMT
must be weighed not only against potential adverse sequelae of the electric fields but also
the physical risk of electrode implantation in and around CNS tumors. One of the most
feared surgical complications of brain surgery is intracerebral hemorrhage (ICH) and data
reported from common neurosurgical procedures may help estimate the ICH risk of IMT.
For example, stereotactic brain biopsies are performed to obtain tissue diagnosis and may
involve collection of several core tumor samples. Biopsy studies from the last three
decades have cited reasonably low incidence of clinically-relevant ICH, including 1.4%
ICH-related major deficits or death after image-guided brain biopsies in 300 patients
[Bernstein, 1994], 1.2% hemorrhage-related neurological deficits in 500 consecutive
biopsies [Field, 2001], 4% incidence of symptomatic ICH in 270 patients [27], and 2.6%
transient ICH-related symptoms in an 80-patient cohort [Mizobuchi, 2019]. Similarly low
ICH risk has been associated with laser interstitial thermal therapy (LITT), a minimally
invasive cancer procedure using stereotactic placement of a laser probe to ablate a target
brain tumor [Holste, 2019]. A series of 100 LITT cases with various neuro-oncological
pathologies reported a 4% complication rate, none of which were hemorrhagic in nature
[Shah, 2020]. Another study of 58 LITT outcomes in de novo and recurrent GBM found a
15.5% overall complication rate mostly related to edema and seizures, with 1 mortality
from hemorrhage in a large tumor [Kamath, 2019]. Consistently, a recent review of 17
reports and 203 patients with recurrent GBM receiving LITT found a 0.5% incidence of
hemorrhage [Montemurro, 2020]. Other neurosurgical procedures involving implantation
of multiple brain electrodes, such as DBS and stereo electroencephalography (sEEG),
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also have acceptable complication profiles. Most bleeding events associated with these
surgeries are small and have no overt clinical sequelae [Tonge, 2015]. DBS often entails
placement of one or two permanent electrode leads and, over the past two decades, has a
reported ICH incidence 1.0% to 3.4% per lead [Liu , 2015; Binder , 2005; Ben-Haim ,
2009; Falowski , 2015]. sEEG used for seizure monitoring can be associated with
numerous implanted brain electrodes [Cardinale, 2016]. In 30 reports describing
outcomes of 2624 sEEG patients, the pooled incidence of ICH was 0.7% [Mullin, 2016].
Two additional series described 549 consecutive sEEG implantations (total 7029
electrodes) with 1.5% symptomatic ICH [40] and 742 patients with 0.03% of clinicallyrelevant ICH [Cardinale, 2016; McGovern, 2019]. The overall low complication risk,
including that of ICH, associated with these neurosurgical procedures supports the safe
feasibility of a multi-electrode IMT approach for CNS cancer.
This study sheds new light on the potential of electric field treatment for brain cancer and
introduces the utility of phase-shifted waveforms to produce broad, consistent tumor
coverage. It offers a novel demonstration of computer simulation, programming and
efficacy of dynamic field IMT in patient-derived HGG. Within the limits of the treatment
models, the current multi-modality analysis provides compelling evidence of IMT
susceptibility in patient glioma specimens without harmful effects in normal living brain.
The essential next steps in the translational pipeline will be definition of key technical
elements and impact of dynamic field therapy in vivo and in combination with
chemotherapy and radiation. The present data support the intriguing prospect of IMTbased strategies in neuro-oncology.
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Chapter 5

5

Discussion

5.1 Summary of Major Results
My thesis was designed to address three major research goals. First, we aimed to develop
and test a unique set of IMT stimulation parameters outside the range of neural
entrainment and establish both in vitro and in vivo models of GBM. Using these and other
methods, we next aimed to define the efficacy of IMT treatment for the highly fatal
pediatric brain tumor DIPG. Finally, we aimed to apply these concepts to improve IMT
hardware and test treatment effect in completely novel, 3D patient-derived HGG models.
The work presented in this thesis yielded key information that allowed expansion of the
IMT treatment paradigm to other CNS neoplasms, led to improved IMT delivery and, for
the first time, directly demonstrated the preferential impact of IMT against HGG
compared to non-neoplastic normal human brain.
The research presented in Chapter 2 aimed to address the need for intermediate frequency
(200 kHz) stimulation IMT electric fields that is beyond the range of neural entrainment.
Additionally, we aimed to translate these novel stimulation parameters into cultures with
primary patient GBM cells and in an F98 Fischer rat syngeneic glioma model. We
hypothesized that intermediate-frequency IMT electric fields will provide a novel,
effective means of primary tumor control both in vitro and in vivo. IMT produced tumorselective cell death of primary patient-derived GBM cells in vitro. IMT-treated cells
demonstrated reduced cell density and a pyknotic morphology compared to the sham
cells. Analysis of viability revealed a significant reduction in cellular metabolic viability
in the IMT treatment group. In contrast, when rat cortical neurons were treated with
either sham or IMT, no difference in cellular viability was detected, suggesting that our
200 kHz treatment parameters are selective for neoplastic, highly-proliferative cells and
will not harm the normal brain parenchyma [DiSebastiano, 2018]. Preliminary studies
into the mechanisms of IMT in vitro demonstrated robust activation of apoptotic markers
and programmed cell death; however, the initiation factors of the apoptotic pathways are
yet to be elucidated. These findings prompted the translation of IMT into an F98 Fischer
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rat glioma model. Bilateral orthotopic tumors were established by implanting F98 cells
into the caudate putamen of syngeneic adult Fischer rats, following a protocol established
by Mathieu et al. [DiSebastiano, 2018; Desmarais, 2012; Mathieu, 2007; Mathieu, 2005;
Lenting, 2017; Barth, 1998]. Utilizing this model, we were able to assess F98 tumor
growth, treatment effect of IMT, and the effects of IMT on the normal brain parenchyma.
We observed a significant ~20% reduction in tumor volumes in tumors treated with a 7day course of first-generation IMT compared to their respective internal sham controls.
These results, though exciting, raised the question of why we observed a limited
treatment effect of IMT in vivo compared to in vitro studies. Utilizing a computational
workflow, our team determined that the rudimentary single electrode hardware only
delivered electric fields of 1 V/cm across 24% of the tumor volume and was insufficient
for generating the electric fields necessary to encompass the robust tumors grown in the
F98 model. These observations prompted the development of multi-electrode hardware to
extend electric field coverage across these tumors and to surrounding tumor-affected
brain regions.
The development of the methods outlined in Chapter 2 allowed for the investigation and
application of IMT for DIPG, another HGG, which was explored in Chapter 3. We aimed
to determine the responsiveness of DIPG to IMT in combination with chemoradiotherapy
in vitro. Based on the findings from Chapter 2, we hypothesized that IMT in combination
with chemoradiotherapy would provide an effective means to increase drug sensitivity
and reduce viability of patient-derived DIPG cells. We demonstrated the in vitro efficacy
of intermediate-frequency IMT on primary DIPG patient tumors. IMT as a monotherapy
profoundly reduced the viability of patient derived DIPG cells (~50%) and was
determined to be apoptosis mediated. The addition of IMT to the combined TMZ-RT
paradigm dramatically reduced DIPG cell viability from ~ 60% to 20% [Deweyert,
2019]. To date, the effects of the combination therapies appear to be additive in DIPG
cells. To our knowledge, this research is the first to demonstrate the innate sensitivity of
DIPG cells to perturbations in their local electrical environment. The results presented in
this chapter highlight that all patient derived DIPG cell cultures tested were sensitive to
IMT monotherapy, and that IMT increased the efficacy of the current standard of care in
vitro. We also observed DIPG cells treated with IMT to have an increased sensitivity to
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chemotherapeutics. These findings are exciting as DIPG remains recalcitrant to current
pharmacological interventions, and IMT may offer a method of drug delivery and
sensitization. These proof-of-concept findings demonstrate the potential of IMT as a
novel electrotherapeutic strategy for the treatment of DIPG and support further
investigation of IMT for other primary CNS neoplasms and metastases.
The research presented in Chapter 4 builds upon that of previous chapters. Guided by
these studies, we aimed to improve the delivery of IMT electric fields through the
development of multi-electrode hardware and novel phase-shifted stimulation parameters
[DiSebastiano, 2018; Iredale, 2020]. To test the efficacy of newly designed IMT delivery
systems, we developed a high throughput 3D model of GBM that emulates the growth
and invasive properties of HGGs. Therefore, we hypothesized that multiple IMT
therapeutic electrodes will produce electric fields that cover the extent of HGGs,
increasing the therapeutic effect of IMT, without negatively impacting the surrounding
brain parenchyma. Chapter 4 provided novel evidence of GBM cell vulnerability to
phase-shifted, low-intensity electric fields delivered using a high throughput, preclinical
IMT protocol. Phase-shifted IMT reduced the viability of tumor cells and prevented
tumor invasion of the peritumoral matrix using stimulation parameters previously
demonstrated to be non-injurious to normal neural cells [DiSebastiano, 2018; Deweyert,
2019, Hu, 2016; Rominiyi, 2021; Kirson, 2009; Pless, 2011; Mittal, 2017]. IMT
monotherapy reduced GBM cell viability by ~50% in spheroid cultures; this effect was
amplified on the exquisitely sensitive BLI studies that showed ~90% reduction in signal.
Cultures exposed to IMT treatment displayed limited growth, and in some cases, a
reduction in tumor mass. Tumor cell invasion was also limited by IMT therapy,
suggesting that IMT may not only eliminate the bulk of the tumor mass, but also
effectively treat the invasive GBM cells responsible for disease recurrence. Studies with
naive GBM organoids recapitulated the spheroid results and represent first time evidence
of human disease sensitivity to IMT. Future studies are needed to investigate the
combinatory effect of IMT with chemoradiation in 3D models to determine if IMT exerts
synergistic treatment effects. Control studies were preformed to assess the safety of
multi-electrode phase shift IMT on both non-neoplastic brain organoids and normal brain
parenchyma. In these studies, IMT was delivered in vitro to non-tumor brain tissue and to
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rat brains. Results showed that the hardware and treatment parameters did not reduce the
viability of the non-neoplastic brain organoids and was well tolerated with no observable
behavioral or histological changes due to treatment in the animals. These studies help
provide evidence that IMT and phase shift are safe and well tolerated in a living system.
Though the effects of multi-electrode, phase shift IMT have not been tested in vivo, we
hypothesize that the field planning methods and delivery system outlined in these
preclinical models will translate well to in vivo applications. We envision IMT as a
source of chronic, highly selective, therapeutic fields that combat the infiltrative nature of
HGGs and highly fatal brain cancers.

5.2 Experimental Limitations
While we have made marked progress in the development of IMT towards human use,
we still have not shown the efficacy of IMT in human HGG using in vivo models. To do
this, we would require translation to a human patient-derived xenograft (PDX) model and
hopefully human trials will follow. To date, we have shown significant but limited
efficacy of single electrode IMT in a Fischer rat F98 animal and have yet to translate the
newly developed multi-electrode design, which is expected to improve tumor coverage
and response. We used a single 3-electrode construct for convenience in the preclinical
models here, however we would envision various, personalized multiple electrode
strategies, such as multiple implantable electrode leads and or arrays, in human
application. While the Fischer rat F98 model has been a useful, highly reproducible tool
to explore these novel treatment paradigms, it has a few limitations that have likely led to
the underestimation of treatment effect. For example, the highly rapid tumor growth rate
in the F98 model is far beyond that observed in human tumors and PDX models. The
tumors rapidly progress from 40,000 cells on the day of implant to encompassing the
entire hemisphere by day 11. The treatment fields tested to date have not been designed
to encompass a rapidly expanding tumor and is likely that the tumor growth is beyond the
borders of the electric fields before the initiation of treatment. Thus, these tumors can
grow uninhibited in these regions, limiting observed treatment effect. Additionally, this
model lacks some key features of human HGG that are integral to understanding disease
recurrence and progression, such as the molecular drivers of disease and the hallmark
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migration and invasion into the surrounding brain parenchyma. It is likely that studies
utilizing the Fischer F98 model will be effective for determining the efficacy of IMT
against the bulk tumors mass. To understand the role IMT against diffuse infiltrative
disease, additional humanized models will need to be developed.
The treatment effect of IMT in vivo may be limited by the analysis methods.
Quantification by stereology was unable to distinguish necrotic centers of the large F98
tumors from areas of IMT induced cell death. For this reason, treated tumors likely have
an overestimation of viable tumor volume, and conservative estimates of treatment effect
in vivo. While these conservative findings show great promise for the further
development of IMT, it will be important to overcome this limitation to fully understand
the degree of treatment efficacy. The addition of highly sensitive tumor monitoring and
imaging techniques such as BLI and MRI in conjunction with stereology is expected to
improve our understanding of treatment effect.
Another limitation of the current IMT models is the relatively short duration of treatment.
Our current models do not allow for longer than one week delivery of IMT fields, due to
the need for media changes in vitro and the aggressive nature of the F98 cells in vivo,
causing animals to quickly reach humane end points. Short treatment duration has likely
led to underestimation of the ability of IMT to control disease. A potential future study
will be the implementation of longitudinal IMT. The study will require the development
of appropriate rat and large animal PDX models that demonstrate a reduced rate of
disease progression more akin to human disease. Longitudinal IMT experiments will be
able to assess treatment effects over an undefined period, and the animals can be
followed with medical imaging such as MRI and BLI to monitor disease progression.

5.3 Future Directions
My work, in conjunction with concurrent team collaborations, has substantially advanced
our knowledge of IMT efficacy and improved delivery strategies for treatment of
devastating HGGs. This thesis demonstrated that IMT attenuates HGG growth in novel in
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vitro models and in a syngeneic rat glioma model. With our collaborative research team,
we established a phase shifted treatment parameters, and implement both a multielectrode IMT hardware and new optimized stimulation parameters. The next critical step
will be to translate the in vitro findings presented in this thesis to in vivo models. IMT
will be tested in the syngenetic F98 Fischer rat model; however, due to limitations of this
model, it is also critical to develop a host of PDX models using patient derived cells to
better recapitulate human disease. These models may include PDX models in
immunodeficient rats (in-house model is in development), which will provide long-term
GBM engraftment and growth [Noto, 2020]. The human HGGs transplanted into these
models behave more like patient tumors and better recapitulate the genetics and tumor
behavior that the current F98 model lacks. Specifically, the rate of xenograft growth
emulates growth seen in patients, with tumors growing over many weeks. Perhaps most
importantly, these models demonstrate parenchymal infiltration and a genetic profile that
mimics human patients [Stringer, 2019]. These newly developed PDX models will allow
for the implementation of longitudinal IMT studies and will be able to assess treatment
effects over an undefined period. Additionally, animals may be followed with medical
imaging such as MRI and BLI to monitor disease progression [Parkins, 2016].
Demonstrating a quantifiable and measurable increase in lifespan with IMT is a necessary
step towards the goal of clinical translation.
To date, we have primarily explored IMT as a monotherapy of HGGs, with some
evidence of the efficacy of combination therapies with the standards of care for GBM in
vitro [DiSebastiano, 2018; Deweyert, 2019; Hu, 2016]. Though we predict to see a
positive treatment effect of combining multi-electrode IMT with chemoradiotherapy in
vitro, it remains largely unknown if these benefits will translate in vivo. Utilizing our
established animal model, we can begin to explore these combination therapies in living
systems.
It is evident from our studies that IMT initiates apoptotic pathways leading to cell death;
however, how these pathways are initiated and why they are selective to neoplastic cells
compared to the normal brain parenchyma is poorly understood. The underlying
mechanisms may involve interference with cytokinesis and/or more complex mechanism
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involving membrane channels and cell permeability [Chang, 2018; Karanam, 2020;
Serpersu, 1985; Wei, 2015; Penuela, 2012]. Overall, further investigation is required to
better understand the underlying mechanisms of how IMT exerts anti-neoplastic effects
and attenuates tumor growth. Understanding these mechanisms may allow for further
guidance in the optimizing stimulation parameters and could potentially improve IMT
treatment efficacy as a monotherapy and in combination with standard and other
burgeoning therapies.

5.4 Significance and Overall Conclusions
There is a dire need for new treatments for rapidly fatal HGGs. The work in this thesis
clearly demonstrated the efficacy of a novel treatment modality, IMT. IMT selectively
kills HGG cells over normal neural cells and takes advantage of the innate
electrosensitivity of neoplastic cells while remaining inert to normal brain parenchyma.
We have conclusively demonstrated that GBM and DIPG cells are susceptible to lowintensity electric fields delivered using an implantable/indwelling system, which are a
powerful and titratable force that matches the diffuse infiltrative nature of these diseases.
We have discovered that IMT provides highly effective primary anti-neoplastic control in
vitro and displays proof-of-concept efficacy in animal models. Importantly, IMT also
markedly increases tumor sensitivity to concurrent chemoradiation. The newly-developed
IMT technology is readily translatable, and we think may offer safe and feasible human
application. The collaborative interdisciplinary data presented within this contributes to
the fundamental framework which establishes IMT as a putative new and effective
therapeutic modality for highly-fatal brain cancers.
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